

**REMARKS**

Reconsideration and allowance of the above-identified application are respectfully requested. Claims 318, 320, 322, 323, 328 and 331-355 are in the case.

**I.      Interview of March 28, 2003**

The undersigned wishes to thank Examiners Scheiner and Housel for their time and considerations of the issues during the interview of March 28, 2003. It is believed that the interview materially advanced prosecution of the subject application.

It was agreed that the finality of the Official Action dated February 10, 2003 would be withdrawn. Further, the Examiners expressed a high likelihood that the subject matter of claims 332 and 333 (now claims 332-355) would be rejoined to the elected invention.

Applicants agreed to submit evidence of enablement by providing data on additional viral strains, as well as evidence relating to local versus systemic administration.

Claims which the Examiner stated were elected in paper 31 page 2 (or also paper 48 page 2), were reintroduced in the previous Amendment:

claim 332 is similar to old claims 164;

and

claim 333 is similar to old claim 177.

Support for amended claim 333 (and new claims 334-346 and 344-347) can be found on page 11 of the specification.

New independent claim 343 and its dependent claims, also relate to a method of treating cancer by systemic administration of NDV, but also require more than one dose of the virus.

New independent claim 355 relates to a method of treating cancer in a mammal having a tumor comprising administering intravenously to said mammal more than one dose of a Newcastle Disease Virus an amount sufficient to cause tumor regression.

## **II. Prior Rejections of Claims 164,165,167,168 and 177**

### **Lack of Enablement**

In the Official Action of May 26, 1998, page 3, the Examiner rejected claims 164, 165, 167, 168 and 177 under 35 USC 112 first paragraph. The Examiner alleged that “the specification teaches only the use of NDV 73-T strain which is not sufficiently enabling for all NDV strains, or any mesogenic strain.” The Examiner also alleged that “systemic administration has not been taught in the specification (claims 164-168).”

### **Newcastle Disease Virus (NDV)**

The subject patent application specifically exemplifies *two* NDV strains to treat cancer (Mass MK 107 and 73-T). In the specification, there is an example (Example 3, page 27 along with Figure 5) of tumor regression using an NDV strain other than 73-T: the strain Mass MK107. Mass MK107 is a well-known NDV strain.

Further support that the disclosure made in the subject application regarding NDV is enabling can be found in commonly owned U.S. Serial No. 09/292,376, (now U.S. Serial No 10/167,652) where there are examples of antitumor efficacy with two other strains of

NDV in Examples 21, 22, 23. This is in addition to the extensive examples (Examples 1-10, 16-17, 29 and including an example with human clinical data - Example 20) that used Mass MK107, the mesogenic strain of NDV. This evidence of successful results with additional strains of NDV confirms the statement of applicants in the subject application that NDV generally, and not just the exemplified strains, can be used in accordance with the claimed method.

### **Systemic Administration**

The term "systemically" is supported in the specification on page 13: "the virus can be administered either directly at the tumor site by local or regional injection, or systemically." See also Example 2 relating to systemic NDV therapy.

Intravenous and intraperitoneal administration are taught in the subject specification. See page 13 first full paragraph: "The virus is preferably administered to the mammal by injection (e.g. intravenous...intraperitoneal....)"

Further support that the disclosure made in the subject application regarding intravenous administration is enabling can be found in commonly owned Serial No. 09/292,376, (now U.S. Serial No 10/167,652) where additional examples are provided of antitumor efficacy using the intravenous route with mesogenic MK107 strain: Examples 3, 9 and 20 (with Example 20 showing clinical human experience of systemic treatment including regressions of 5 tumors). In this regard, also see the attached 2002 article by Pecora et al entitled "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers." The Pecora article shows the results of a Phase I trial where patients with tumors were treated by intravenous administration of PV 701

(triple plaque purified Mass MK107) as a single dose or in multiple doses. This evidence of successful results (including tumor regression and freedom from tumor progression) with systemic administration confirms the statement of applicants in the subject application that systemic administration as a single dose or as multiple doses, can be used in accordance with the claimed method.

### **Multiple Doses**

On page 13 of the specification it is stated: “It is also understood that it may be necessary to give more than one dose of the virus.” See also Example 2 where multiple systemic doses were given.

### **Tumor Regression**

Support for the phrase “tumor regression” can be found throughout the specification, e.g. Example 2. Support for the dosages specified in dependent claims 342, 351 and 352 can be found on page 13 and in Example 2.

35 USC 112 first paragraph has no requirement that every embodiment of a claim be exemplified. The claims are enabled as written. The description in the subject specification, the examples therein, as well as subsequent data discussed above, all support that the claims as presented are sufficiently enabled, i.e. the skilled person would know how to make and use NDV for the claimed use.

**Previous Prior Art Rejections**

In the Official Action dated July 8, 1997, the Examiner rejected claims 164, 165 and 177 under 35 USC 102(b) as being anticipated by Bohle et al., Cassel et al., or Murray et al.

Applicants responded in an Amendment dated January 8, 1998, noting that: each of these references involves the administration of virus and tumor cells to boost an immune response against antigens present on the tumor cells. The administration in these references was not *systemic administration*.

These 102 rejections were not repeated in the next Official Action (May 26, 1998).

In the Official Action dated May 26, 1998, claims 164, 165, 167, 168 and 177 were rejected under 35 U.S.C. §102(b) as allegedly anticipated by Lorence et al (1988).

Lorence et al discusses *in vitro* tumor cell data. There is no *in vivo* data and no discussion of systemic administration, dosage or multiple doses.

Also in the May 26, 1998 Action, claims 164, 165, 167, 168 and 177 were rejected under 35 U.S.C. §102(a) as allegedly anticipated by Reichard et al (1992); and rejected under 35 U.S.C. §102(b) as allegedly anticipated by Reichard et al (1992).

In response to a declaration by Robert Lorence filed on June 30, 1995, the Examiner stated in her Official Action dated October 18, 1995 at page 4: "The Lorence Declaration is acknowledged, The Katz declaration is sufficient to remove the Reichard et al reference."

The Examiner's attention is also directed to the attached article by Schirrmacher et al (2001) entitled "Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects." In the article, the authors note "Systemic anti-metastatic effects were never observed with NDV alone in contrast to previous results obtained with NDV modified tumor vaccines." This article teaches away from the claims of the subject invention.


Should any small matters remain outstanding, the Examiner is encouraged to telephone Applicants' undersigned attorney at the number noted below so that same can be resolved without the necessity of an additional action and response thereto.

Allowance of the application is awaited.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
Attachments: Pecora et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers."  
Schirrmacher et al (2001), "Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects."

## Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers

By Andrew L. Pecora, Naiyer Rizvi, Gary I. Cohen, Neal J. Meropol, Daniel Sterman, John L. Marshall, Stuart Goldberg, Peter Gross, James D. O'Neil, William S. Groene, M. Scot Roberts, Harvey Rabin, Michael K. Bamat, and Robert M. Lorence

**Purpose:** PV701, a replication-competent strain of Newcastle disease virus, causes regression of tumor xenografts after intravenous administration. This phase I study was designed to define the maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer.

**Patients and Methods:** Seventy-nine patients with advanced solid cancers that were unresponsive to standard therapy were enrolled. Four PV701 intravenous dosing regimens were evaluated: (1) single dose: one dose every 28 days; (2) repeat dose: three doses in 1 week every 28 days; (3) desensitizing: one lower dose followed by two higher doses in 1 week every 28 days; and (4) two week: one lower dose followed by five higher doses over 2 weeks every 21 days.

**Results:** A 100-fold dose intensification was achieved over 195 cycles. A first-dose MTD of  $12 \times 10^9$  plaque-forming units (PFU)/m<sup>2</sup> was established for out-

patient dosing. After an initial dose of  $12 \times 10^9$  PFU/m<sup>2</sup>, patients tolerated an MTD for subsequent doses of  $120 \times 10^9$  PFU/m<sup>2</sup>. The most common adverse events were flu-like symptoms that occurred principally after the first dose and were decreased in number and severity with each subsequent dose. Tumor site-specific adverse events and acute dosing reactions were also observed but not cumulative toxicity. Objective responses occurred at higher dose levels, and progression-free survival ranged from 4 to 31 months. Tumor tissue from one patient was obtained after 11 months of therapy and showed evidence of PV701 particles budding from the tumor cell membrane by electron microscopy and a pronounced lymphoplasmacytic infiltrate by histologic examination.

**Conclusion:** PV701 warrants further study as a novel therapeutic agent for cancer patients.

*J Clin Oncol* 20:2251-2266. © 2002 by American Society of Clinical Oncology.

PV701<sup>1,2</sup> IS A HIGHLY purified, replication-competent, naturally attenuated strain of Newcastle disease virus,<sup>3-6</sup> an avian paramyxovirus. Newcastle disease virus strains, such as PV701, directly lyse diverse human cancer cells in vitro (oncolytic) while being significantly less toxic toward normal human cells.<sup>1,3,7</sup> Moreover, the virus is capable of both stimulating T-cell-mediated specific antitumor immunity and inducing nonspecific activation of immune function, such as the induction of cytokines (eg, interferon) and activation of tumorcidal macrophages.<sup>8-10</sup>

Newcastle disease virus is a rapidly replicating RNA virus with progeny virions first detectable in vitro within 3 hours after infection. After infecting a cancer cell, the virus rapidly spreads to neighboring tumor cells through the release of progeny virions and syncytia formation.<sup>3,11</sup> PV701 and certain other negative strand RNA viruses are selectively cytotolytic for tumor cells as a result of defects in the interferon (IFN) signaling pathway that are common among diverse tumor types.<sup>12,13</sup> Defects in this pathway are believed to confer a growth and survival advantage to tumor cells.<sup>13-16</sup> However, these tumor defects also disable the antiviral function of IFN and confer sensitivity of malignant cells to infection and replication of viruses such as PV701.

Oncolytic Newcastle disease virus strains, including PV701, administered via intravenous, intraperitoneal, and intratumoral routes, replicate selectively in human cancer cells implanted in athymic mice, resulting in high rates of

complete tumor regression and sparing of normal tissue.<sup>2,3,17,18</sup> In vitro death for most tumor cell lines occurs at a PV701 amount ~1,000-fold below the amount that adversely affects normal cells.<sup>1</sup> Similarly, there is an ~1,000-fold difference in the intravenous dose resulting in 50% tumor regression in athymic mice ( $\sim 2 \times 10^6$  plaque-forming units [PFU]/mouse) and the median lethal dose ( $\sim 5 \times 10^9$ ) in these mice.<sup>2</sup> In these animals, clear dose and dose frequency effects are observed, providing the rationale for examining such effects in the clinical setting. Objective

---

From the Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC; The Cancer Center at Greater Baltimore Medical Center, Baltimore, and Pro-Virus, Inc, Gaithersburg, MD; and Fox Chase Cancer Center and University of Pennsylvania Medical Center, Philadelphia, PA.

Submitted August 6, 2001; accepted February 4, 2002.

Supported by Pro-Virus, Inc, Gaithersburg, MD, through Clinical Trial Agreements.

Presented in part at the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

Address reprint requests to Andrew L. Pecora, MD, Hackensack University Medical Center, Northern New Jersey Cancer Center, 20 Prospect Ave, Suite 400, Hackensack, NJ 07601; email: apecora@humed.com.

© 2002 by American Society of Clinical Oncology.  
0732-183X/02/2009-2251/\$20.00

responses (complete response and partial response) increase from ~50% to 100% by raising the dose three-fold or increasing the number of doses given at the same dose level from one to three doses.<sup>2</sup> In addition, intravenous exposure to a lower first dose of PV701 ( $3 \times 10^8$  PFU/mouse) results in a desensitization of the animal to toxicity from subsequent doses as evidenced by a 10-fold increase in the maximum-tolerated dose (MTD) for dose 2 ( $10^{10}$  PFU/mouse) compared with dose 1 ( $10^9$  PFU/mouse). The oncolytic effect of PV701 requires live replication-competent virus because UV-inactivated virus caused no tumor regression.<sup>2</sup>

Oncolytic activity associated with Newcastle disease virus was first observed by Cassel and Garrett<sup>19</sup> when an intratumoral injection in a patient with cervical cancer resulted in tumor regression of the injected mass as well as a supraclavicular lymph node metastasis. Subsequent clinical trials of Newcastle disease virus focused primarily on a vaccine approach using viral oncolysates that included low doses of viable virus infecting autologous tumor cells.<sup>8,20,21</sup>

Characteristics of Newcastle disease virus that are favorable for human trials include the genetic stability of vaccine strains, the absence of genetic recombination, lack of a carrier state of naturally attenuated strains, and the lack of antigenic drift.<sup>3</sup> Human-to-human transmission has not been observed.<sup>6</sup> The virus has been safely given to humans in tumor vaccine studies, and accidental exposure has been reported to cause only self-limiting conjunctivitis.<sup>3,5,6</sup>

Other replication-competent viruses, including adenovirus and herpes simplex virus alone or in combination with chemotherapy, have caused tumor regressions in humans by the intratumoral route.<sup>22-24</sup> Early testing of both replication-competent and replication-incompetent adenoviruses by the intravenous route has been initiated,<sup>25,26</sup> but, until now, there has been no determination of the MTD for systemic therapy with a virus. Herein we report on a phase I study with dose escalations including the testing of various treatment schedules and MTD determination for systemic (intravenous) administration of the replication-competent virus PV701 in patients with advanced cancer that was unresponsive to standard therapy.

## PATIENTS AND METHODS

### *Patient Enrollment*

Seventy-nine patients were enrolled with advanced or metastatic solid malignancy that was unresponsive to treatment with established therapies. Entry criteria included at least one bidimensionally measurable tumor,  $\geq 18$  years of age, a life expectancy of at least 3 months, and a performance status (Eastern Cooperative Oncology Group) of 0 or 1. Laboratory result minimum entry requirements included 3,000 WBCs/ $\mu$ L, 1,500 neutrophils/ $\mu$ L, and 100,000 platelets/ $\mu$ L. Also

required was a serum creatinine level less than 1.5 times the upper limit of normal, serum transaminase level less than 2.5 times the upper limit of normal (< 5.0 times the upper limit of normal for patients with metastatic liver disease), and a therapy-free period of 14 days. Patients were not eligible if documented to have CNS disease (including brain tumors on computed tomography [CT]/magnetic resonance imaging [MRI] scans required at screening), known hypersensitivity to eggs, antiviral or systemic corticosteroid treatment within 14 days, myocardial infarction or life-threatening arrhythmia within 6 months, known positivity for human immunodeficiency virus, active hepatitis B or C infection, an organ allograft, autoimmune disease, active viral infection (including cold or influenza), or uncontrolled bacterial infection. Active poultry workers and pregnant or nursing women were excluded. All patients provided informed written consent approved by the appropriate institutional review board.

### *PV701*

PV701 is a highly purified isolate of the naturally attenuated (nonrecombinant) MK107 vaccine strain of Newcastle disease virus and is distinct from other strains, such as 73-T, that have been previously tested in humans. PV701 was cloned from MK107 by biologic means (triple-plaque purification in chicken embryo cells) to increase homogeneity and to remove defective particles. PV701 was grown to high titer in specific pathogen-free embryonated chicken eggs (SPAFAS, Inc, Preston, CT) and purified from allantoic fluid. Clinical lots of PV701 used in this study met release criteria, including potency, purity, sterility, and adventitious agent testing (Investigational New Drug Application BB 7401, May 7, 1998).

### *Plaque Assay*

Doses were expressed as the amount of infectious virus in PFU. For the plaque assay, HT1080 human fibrosarcoma cells (obtained from American Type Culture Collection, Manassas, VA) were seeded into six-well tissue culture plates and grown to confluence. The growth medium was removed, monolayers were washed with serum-free medium, and 0.5 mL of various sample dilutions were added per well. The plates were incubated with rocking for 90 minutes at 37°C and 5% CO<sub>2</sub>. The medium was completely removed, the monolayers were washed as above, and 3 mL of semisolid agar medium was overlaid onto each well. The cultures were incubated for 48 hours at 37°C and 5% CO<sub>2</sub>. Monolayers were stained with neutral red for counting of plaques, and the virus titer was expressed as PFU/mL.

### *Intravenous Administration of PV701*

For the first 47 patients, PV701 was prepared in a sterile syringe and patients were administered the dose over 10 minutes (regardless of dose level) by injection of the syringe contents into a port on a running intravenous line (at  $\sim 25$  mL/h). For the subsequent 32 patients, PV701 was diluted into an intravenous saline bag (50 to 100 mL) immediately before dosing and administered at a rate of  $1.2 \times 10^9$  PFU/m<sup>2</sup>/min for doses of  $12 \times 10^9$  PFU/m<sup>2</sup> and at a rate of  $5.0 \times 10^9$  PFU/m<sup>2</sup>/min for doses greater than  $12 \times 10^9$  PFU/m<sup>2</sup>.

### *Treatment and Study Design*

**Single-dose regimen.** A single dose of 5.9, 12, or  $24 \times 10^9$  PFU/m<sup>2</sup> was administered every 28 days (n = 17 patients). The starting dose of  $5.9 \times 10^9$  PFU/m<sup>2</sup> was selected because this dose was greater than 1 log below the rodent MTD on the basis of body surface area. Dose

escalation proceeded by two-fold increments. All patients were hospitalized for 24 hours with intensive monitoring.

**Repeat-dose regimen.** Two dose levels were examined ( $n = 13$  patients): either  $5.9 \times 10^9$  PFU/m<sup>2</sup> or  $12 \times 10^9$  PFU/m<sup>2</sup> was administered three times in 1 week every 28 days. Dose 2 was given 2 days after dose 1.

**Desensitizing regimen.** Five dose levels were examined ( $n = 37$  patients): all patients received  $12 \times 10^9$  PFU/m<sup>2</sup> (desensitizing dose) on the first day of administration followed by two doses of  $24 \times 10^9$  PFU/m<sup>2</sup>, two doses of  $48 \times 10^9$  PFU/m<sup>2</sup>, two doses of  $72 \times 10^9$  PFU/m<sup>2</sup>, two doses of  $96 \times 10^9$  PFU/m<sup>2</sup>, or two doses of  $144 \times 10^9$  PFU/m<sup>2</sup>. Dose 2 was given 2 days after dose 1. For each patient, all three doses were administered within 1 week and repeated every 28 days.

**Two-week regimen.** Two dose levels were examined ( $n = 12$  patients): All patients received  $12 \times 10^9$  PFU/m<sup>2</sup> (desensitizing dose) on the first day of administration followed by five doses of  $96 \times 10^9$  PFU/m<sup>2</sup> or five doses of  $120 \times 10^9$  PFU/m<sup>2</sup>. Dose 2 was given 4 days after dose 1. Patients were given three doses per week for 2 weeks (six total doses) followed by 1 week off treatment. Enrollment was for a minimum of two courses.

**General.** Patients were monitored before each treatment and extensively after treatment. Evaluations included physical examinations, measurement of performance status, laboratory parameters, viral shedding (urine and sputum), and serum testing for PV701 antibodies and infectious virus. CT or MRI was used to assess tumor responses after each course of therapy.

A minimum of three patients were entered at each PV701 dose level until a patient experienced a dose-limiting toxicity (DLT). When a DLT was encountered, three additional patients were enrolled at that same dose level. There was no further dose escalation when two or more patients experienced a DLT. The MTD was defined as the dose level below that at which two or more DLTs were encountered.

Adverse events were graded using the Southwest Oncology Grading Scale. DLT was defined as a clinically significant adverse event (grade 4 leukocyte or neutrophil count lasting  $> 5$  days; platelet count  $< 10,000/\mu\text{L}$  [grade 4 by NCI common toxicity criteria version 2.0]; or  $\geq$  grade 3 nonhematologic excluding fever and fatigue). Transient increases in hepatic transaminases ( $>$  grade 2) without grade 2 hyperbilirubinemia were not considered a DLT if these elevations returned to baseline before the next course. Symptoms clearly related to disease progression were not considered as DLTs.

All patients were eligible for additional courses of treatment when they had at least stable disease and an acceptable toxicity profile.

### Virologic Studies

Samples of urine and sputum were screened for infectious virus by examining for cytopathogenic effects in cultures of HT1080 cells. For these screening assays of urine and sputum, spiked samples with as little as 100 PFU/mL and 100 PFU/g, respectively, were positive. All positive samples were quantified by plaque assay on HT1080 cells (as described in Plaque Assay section).

### Neutralizing Antibody to PV701

Two-fold dilutions of heat-inactivated patient serum were mixed with a PV701 preparation that contained  $3 \times 10^2$  PFU/mL in a total volume of 2 mL. After incubation for 1 hour at room temperature, 0.5 mL of the serum-virus mixture was tested for infectivity using the plaque assay described above. The neutralizing antibody titer of the

serum sample is expressed as the last dilution resulting in at least 80% reduction in the number of plaques.

### Cytokine Measurements

Patient serum was analyzed using commercially available enzyme-linked immunosorbent assay kits for detection of human cytokines (IFN- $\alpha$  and IFN- $\gamma$ , BioSource International, Camarillo, CA; IFN- $\beta$ , Fujirebio, Inc, Tokyo, Japan; interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- $\alpha$ ), Pierce-Endogen, Rockford, IL). Sera from 10 patients were analyzed including two patients who were given a single dose of  $12 \times 10^9$  PFU/m<sup>2</sup>, one patient who was given a single dose of  $24 \times 10^9$  PFU/m<sup>2</sup>, five patients who were given three repeat doses of  $12 \times 10^9$  PFU/m<sup>2</sup>, and two patients in the desensitizing regimen who were given a first dose of  $12 \times 10^9$  PFU/m<sup>2</sup> followed by two doses of  $24 \times 10^9$  PFU/m<sup>2</sup>.

### Tissue Processing

Sections of formalin-fixed patient tissues were processed for hematoxylin and eosin (H&E) staining. Electron microscopy of patient tissue samples was performed by negative staining with uranyl acetate and compared with those from experimental HT1080 human fibrosarcoma xenografts infected with PV701.<sup>2</sup>

### Statistical Analysis

Assessments of the association between age or baseline anemia and grade 3 flu-like symptoms, the association of transaminase elevations ( $> 200$  U/L) and preexisting liver metastases, and the association of preexisting lung disease and oxygen desaturation were performed using Fisher's exact test. The null hypothesis was that the probability of an adverse event was the same in patients with and without the baseline characteristic. A two-sided alternative was considered statistically significant at  $P < .05$ .

## RESULTS

### Patient Characteristics

Seventy-nine patients (48 men and 31 women) with advanced cancer that was unresponsive to standard therapy were enrolled onto this study (Tables 1 and 2) from June 1998 through September 1999 and were treated over 12 dose levels with a total of 195 cycles. The median age was 58 years (range, 24 to 81 years) with 22 patients (28%) older than 70 years. The most common primary tumor types were colorectal ( $n = 23$ ), pancreatic ( $n = 9$ ), renal ( $n = 9$ ), breast ( $n = 8$ ), and non-small-cell lung carcinoma ( $n = 8$ ). Seventy-two patients had received previous chemotherapy; 35 of them received three or more regimens.

### Antibody Response

Thirty-two patients were tested at baseline for neutralizing antibody to PV701. One of these patients was positive at the limit of detection of the assay. His adverse event profile was no different from that of other study subjects. The other 31 patients tested all were negative for neutralizing antibody.

Table 1. Dosage Levels

Dose Level	Regimen	Doses ( $\times 10^9$ PFU/m $^2$ )	Dose Intensity ( $\times 10^9$ PFU/m $^2$ /course)	No. of Patients Enrolled	No. of Cycles
1	Single	5.9	5.9	6	19
2	Single	12	12	6	11
3	Single	24	24	5	13
4	Repeat	5.9 $\times$ 3	17.7	6	8
5	Repeat	12 $\times$ 3	36	7	11
6	Desensitizing	12, 24 $\times$ 2	60	4	10
7	Desensitizing	12, 48 $\times$ 2	108	3	37*
8	Desensitizing	12, 72 $\times$ 2	156	5	14
9	Desensitizing	12, 96 $\times$ 2	204	12	28
10	Desensitizing	12, 144 $\times$ 2	300	13	13
11	Two-week	12, 96 $\times$ 5	492	7	18
12	Two-week	12, 120 $\times$ 5	612	5	13
Total				79	195

\*This cohort includes patient no. 521, who received 34 cycles of PV701 including his most recent 25 cycles at 12/120  $\times$  5 ( $10^9$  PFU/m $^2$ ).

Fourteen of 16 patients in the single-dose regimen, seven of seven patients in the repeat-dose regimen, and six of six patients in the desensitizing-dose regimen became seropositive, first evident 1 to 2 weeks after PV701 dosing. By week 4 after initial dosing, 10 of 12 patients tested in the repeat-dose and desensitizing regimens had neutralizing antibody titers at 1:320 to 1:640. Eight patients were tested at 5 to 10 weeks after initial dosing, and they had a median neutralizing antibody titer of 1:640 (range, 1:80 to 1:2,560). One patient was followed over 18 courses (1.5 years). At month 3, his titer reached a plateau (at 1:2,560) that has persisted through the last time point analyzed (month 18).

#### Virology

A total of 821 sputum samples and 899 urine samples from 67 patients were examined for virus shedding using highly sensitive infectivity assays. Positive samples were quantified by plaque assay. Fewer than 1% of the sputum samples tested were positive. These positive samples contained low PV701 levels (median 26 PFU/g sputum). No PV701 was detectable in the sputum at day 14 or beyond. All repeat course sputum samples were negative. Fifteen percent of all urine samples tested positive at a low level (median, 820 PFU/mL), and all samples were negative 3 weeks after the last dose. Five percent of urine samples analyzed from courses 2 to 6 were positive for PV701. The percentage of patients with transient viruria at any time during a course dropped from a first course high of 54% to 0% in patients who received seven or more courses of PV701.

#### Cytokines

Serum samples from 10 representative patients who were given one or multiple doses (12 or 24  $\times$  10 $^9$  PFU/m $^2$ ) were

analyzed at multiple time points for serum proinflammatory cytokines (IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IL-6, and TNF- $\alpha$ ). Similar patterns of cytokine production were noted for all 10 patients after their first dose of PV701. IFN- $\alpha$  was the predominant cytokine produced in all patients (median peak levels, 20,000 pg/mL) compared with the four other cytokines (median peak levels between 10 and 200 pg/mL). Detectable increases in IFN- $\alpha$ , IFN- $\gamma$ , IL-6, and TNF- $\alpha$  were first seen by 6 hours after dosing with IFN- $\beta$  only detectable at 20 hours after dosing. All four cytokines consistently reached peak levels at 20 hours after dosing and returned to or near baseline by 2 to 3 days after dosing. In patients who received more than one dose of PV701, there was a marked reduction in serum cytokine levels after the second dose compared with the levels seen after the first dose (eg, for IFN- $\alpha$ , a median peak of 13,000 pg/mL noted after the first dose compared with a median peak of 65 pg/mL after the second dose).

#### Toxicity

**Most common adverse events.** Throughout the trial, fever, other cytokine-related flu-like symptoms (eg, chills, fatigue, nausea/vomiting, headache, diarrhea), and hypotension were the most common adverse events (Tables 3 and 4), primarily occurring 4 to 24 hours after PV701 dosing. Except for the immediate dosing reactions (detailed below), adverse events diminished markedly in number and severity with repeat dosing (Table 4) and with the second (see Table 3) and all subsequent courses.

Two of the first three patients in the first cohort (5.9  $\times$  10 $^9$  PFU/m $^2$ ) had grade 3 fever of 40.0°C to 40.6°C, which was promptly reversed with ibuprofen. Beginning with the fifth patient in this cohort, all subsequent patients in this trial received acetaminophen and ibuprofen prophylaxis and the

Table 2. Patient Characteristics

	No. of Patients
Total No.	79
Age, years	
Median	59
Range	24-81
Male:female	48:31
Primary tumor site	
Colorectal	23
Pancreatic	9
Renal	9
Breast	8
Non-small-cell lung	8
Sarcoma	4
Head and neck	4
Melanoma	3
Mesothelioma	2
Esophageal	2
Lymphoma	2
Ovarian	1
Bladder	1
Carcinoma (unknown primary)	1
Cholangiocarcinoma	1
Carcinoid	1
No. of prior chemotherapy regimens	
0	7
1	13
2	24
≥ 3	35
No. of prior immunotherapy regimens	
0	60
1	9
2	10
No. of prior hormonal therapy regimens	
0	69
1	2
≥ 2	8
No. of prior investigational agents	
0	61
1	11
≥ 2	7
Prior surgery	68
Prior radiation therapy	40

incidence of grade 3 fever was reduced to 11% (eight of 75 patients).

In the single-dose regimen, 42% of patients (seven of 17) had at least one episode of diarrhea including one case of grade 4. In subsequent dosing regimens, diarrhea was effectively controlled using loperamide with 10% of patients having diarrhea.

Age and baseline anemia were examined in all 79 patients as potential risk factors for grade 3 flu-like symptoms (fever, fatigue, nausea, vomiting, and dehydration). Age was examined because two DLTs at the  $12/144/144 \times 10^9$  billion PFU/m<sup>2</sup> dose level occurred in elderly patients (81

and 75 years of age; see Dose Escalations, DLT, and Determination of MTD below). Anemia was examined as a risk factor because it might exacerbate the severity of any fatigue, the most common of the grade 3 flu-like symptoms. The analysis showed that 13 (59%) of 22 patients ≥ 70 years of age had grade 3 flu-like symptoms compared with 18 (32%) of 57 less than 70 years of age ( $P < .025$ ), and 24 (52%) of 46 patients with baseline anemia (Hgb < 11 or Hct < 35) had grade 3 flu-like symptoms compared with seven (21%) of 33 patients without baseline anemia ( $P < .01$ ).

*Desensitization to toxicity on repeat dosing.* As predicted from the animal models, dose 1 desensitized patients to the flu-like symptoms on subsequent doses. Table 4 lists the six most common adverse events observed for patients in the desensitizing regimen in order of decreasing incidence and by the Southwest Oncology Group severity grade for each dose. Adverse events were reduced in number and severity after the second and third doses despite a two-fold to eight-fold increase in dose. With all patients receiving prophylactic antipyretics, the incidence of grade 3 fever for patients in this regimen was reduced from 13% on dose 1 to being undetected with subsequent doses (Table 4). The incidence of grade 1 to 2 fever reduced from 83% with dose 1 to 17% with dose 3. A similar pattern of desensitization to adverse events was seen in the 2-week dosing regimen with doses 2 to 6 producing milder and less frequent adverse events compared with dose 1, even when doses 2 to 6 were eight- to 10-fold higher (data not shown). This desensitization to toxicity with repeat doses was also seen for the hematologic changes (see Hematology/Coagulation Profiles below).

*Acute dosing reactions.* Acute and reversible dosing reactions were observed in five of the first seven patients enrolled at the  $12/96/96 \times 10^9$  PFU/m<sup>2</sup> dose level, typically during the third dose of the first course. These reactions consisted of back pain, chest tightness, chest pain, and hypertension. Abdominal pain was less commonly seen. In all cases, the onset was within 5 minutes of the start of dosing and resolved spontaneously and completely within 30 minutes of the beginning of the adverse event. In a few instances, these adverse events required a pause in the administration of virus. One patient experienced grade 3 back pain on his third PV701 injection and was the only patient in the study who did not complete a PV701 dosing because of this acute dosing reaction. All other acute dosing reactions were grade 1 or 2. These reactions were attributed to the rate of administration of the virus, which had increased from  $1.2 \times 10^9$  PFU/m<sup>2</sup>/min at the  $12 \times 10^9$  PFU/m<sup>2</sup> dose level to  $1.0 \times 10^{10}$  PFU/m<sup>2</sup>/min at the higher dose levels. In subsequent patients, the administration rate for doses above  $12 \times 10^9$  PFU/m<sup>2</sup> was decreased to  $5 \times 10^9$

Table 3. Adverse Events for All Patients During the First Two PV701 Courses

Adverse Event	Course 1 (N = 79)			Course 2 (n = 39)		
	Grade 1/2 (%)	Grade 3 (%)	Grade 4 (%)	Grade 1/2 (%)	Grade 3 (%)	Grade 4
<b>Flu-like symptoms</b>						
Fever	92	13	-	59	3	-
Chills	73	-	-	44	-	-
Fatigue/malaise	70	32	-	26	3	-
Headache	34	1	-	5	-	-
Myalgia	23	-	-	13	-	-
Diaphoresis	19	-	-	13	-	-
<b>Gastrointestinal</b>						
Nausea	72	1	1	26	-	-
Vomiting	57	4	1	23	-	-
Anorexia	54	-	-	18	-	-
Diarrhea	53	1	3	15	-	-
Constipation	16	1	-	5	-	-
Dehydration	15	9	-	-	-	-
Dry Mouth	10	-	-	-	-	-
<b>Hematologic</b>						
Thrombocytopenia	46	13	3*	-	-	-
Anemia	38	8	1	13	3	-
Leukopenia	37	23	4†	18	-	-
Increased PT/PTT	30	1	1	15	-	-
Neutropenia	23	8	1	8	-	-
<b>Cardiovascular</b>						
Hypotension	52	5	1	15	-	-
Edema, peripheral	15	3	-	13	-	-
Dizziness	14	-	-	-	-	-
<b>Respiratory</b>						
Dyspnea/hypoxia	27	8	6	15	3	-
Cough	18	-	-	5	-	-
<b>Liver</b>						
Increased ALT/AST	47	18	4	18	3	-
Increased bilirubin	4	10	3	-	-	-
<b>Neurologic</b>						
Pain, back/flank	24	8‡	-	15	3	-
Pain, abdominal	24	4	-	18	3	-
Confusion/disorientation	18	3	-	-	-	-
Anxiety/agitation	13	-	-	5	-	-
Pain, hip/leg	10	-	-	13	-	-
<b>Acute dosing reaction</b>						
Back pain	19	1	-	26	-	-
Chest pain	11	1	-	18	-	-
<b>Metabolic</b>						
Hypokalemia	10	-	-	5	-	-

NOTE. Included are all events with at least a 10% incidence for any grade.

\*For both cases of SWOG grade 4 thrombocytopenia (platelet nadir at  $23,000/\mu\text{L}$  in a patient dosed with a single dose of  $24 \times 10^9 \text{ PFU}/\text{m}^2$  and platelet nadir at  $19,000/\mu\text{L}$  in a patient dosed at  $12/96/96 \times 10^9 \text{ PFU}/\text{m}^2$ ), platelets had recovered to a grade 1 to 2 level within 4 to 6 days and no bleeding was observed.

†All three cases of grade 4 leukopenia occurred 20 hours after dosing and had recovered to grade 2 at the next time point (3 days later).

‡Grade 3 pain occurred in patients with baseline pain at this location.

PFU/ $\text{m}^2/\text{min}$  (see Patients and Methods). At the slower administration rate, dosing reactions occurred infrequently in subsequent patients and were less severe. The symptoms of back pain, chest tightness, and hypertension were suggestive of a vasospasm effect, although no ECG changes were observed and prophylaxis with antihistamines was found to be ineffective.

**Tumor site-specific adverse events including inflammation.** A separate class of adverse events dependent on the tumor location was noted. These tumor site-specific adverse events included the following:

- Tumor inflammation/edema on physical examination (one patient with a scalp metastasis from a colon carcinoma, the other with tongue carcinoma).

**Table 4. Percentage of the Six Most Common Adverse Events Observed for Patients Given Three PV701 Doses for Which Doses 2 and 3 Were Up to Eight-Fold Higher Than Dose 1 (n = 24 patients, desensitizing regimen)**

Adverse Event	Dose 1 (n = 24)		Dose 2 (n = 23)		Dose 3 (n = 23)		Dose 1, Course 2 (n = 14)	
	Grade 1-2 (%)	Grade 3 (%)	Grade 1-2 (%)	Grade 3 (%)	Grade 1-2 (%)	Grade 3 (%)	Grade 1-2 (%)	Grade 3 (%)
Fever	83	13	82	0	17	0	27	0
Chills	54	0	39	0	17	0	20	0
Nausea	46	8	22	0	30	0	13	0
Fatigue	41	38	21	4	26	9	7	0
Vomiting	38	8*	4	0	17	0	7	0
Hypotension	33	0	26	0	4	0	0	0

NOTE. Includes all patients at dose levels 12/24/24 (four patients), 12/48/48 (three patients), 12/72/72 (five patients), and 12/96/96  $\times 10^9$  PFU/m<sup>2</sup> (12 patients).

\*In addition, there was one case of grade 4 vomiting.

- Oxygen desaturation observed only in patients with lung/pleural tumor involvement (13 of 55 patients with pulmonary tumor involvement v zero of 24 without involvement;  $P < .01$ ).
- Pulmonary adverse events (grade  $\geq 3$ , including six cases of grade 3 dyspnea) in nine of 55 patients with pulmonary tumor involvement. Seven of these nine patients had one or more of the following baseline characteristics (signs, symptoms, radiographic evidence): baseline grade 2 dyspnea, lung tumors at least 5 cm in size, significant pleural effusions, partial or complete lobectomy, lobar atelectasis, and lobar consolidation. There were no clinically significant pulmonary adverse events observed in the 24 patients without lung involvement by tumor.
- Transiently elevated liver transaminases over 200 U/L occurred only in patients with liver metastases (18 of 38 patients with liver metastases v zero of 41 patients without;  $P < .01$ ).
- An enterocutaneous fistula at the tumor site (with the tumor extending from bowel to skin surface) in a 63-year-old man with a colon carcinoma occurred 9 days after his first dose of  $144 \times 10^9$  PFU/m<sup>2</sup>.

**Hematology/coagulation profiles.** After the first dose of the first course of PV701, all patients experienced a transient drop in leukocyte and platelet counts with full recovery to baseline observed within 7 to 14 days, regardless of dose level. Clinically significant thrombocytopenia (Southwest Oncology Group grade 4, nadirs of 19,000 and 23,000 platelets/ $\mu$ L) and leukopenia (grade 4) were observed in two and three patients, respectively. However, these patients were carefully monitored clinically with follow-up hematology profiles performed 12 hours to 4 days later and a rapid recovery in blood counts was observed in all cases. No episodes of bleeding or infection resulted from these transient drops in counts. The pattern of thrombocytopenia

and leukopenia was identical for patients who were given one dose as for those who were given up to six doses, indicating that this phenomenon was due to the first PV701 dose. The rate of recovery was the same for the single-dose patients as for those who were given multiple PV701 doses with full recovery noted by day 14 in all patients, including those who were given subsequent doses up to 10 times higher than dose 1. There were no significant changes in leukocyte and platelet counts during subsequent courses.

There were no significant changes in hemoglobin or hematocrit values after PV701 dosing in patients without baseline anemia. Grade 3 anemia was reported for six patients, all of whom had significant anemia at baseline.

Specific assays were added to the standard coagulation panel to serve as early predictors of potential disseminated intravascular coagulation (ie, fibrinogen and fibrin split products). There were no dose- or time-related changes in these parameters or in the standard coagulation parameters (prothrombin time, partial thromboplastin time) that were considered clinically significant and related to therapy.

**Hypoglycemia in patients on oral hypoglycemic agents or insulin.** Three instances of clinically significant hypoglycemia occurred. All three patients had diabetes (two were receiving oral hypoglycemic agents, and one was receiving insulin). After the initial PV701 dose, these patients experienced nausea and dehydration, resulting in limited oral intake. Hypoglycemia was not observed after subsequent PV701 dosing. It is unknown whether PV701 administration also increased the bioavailability of the hypoglycemic therapy. Discontinuing these agents in the immediate post-dosing period after dose 1 resulted in no additional episodes of hypoglycemia.

**Dose escalations, DLT, and determination of MTD.** In the single-dose regimen, doses between cohorts were escalated in two-fold increments from 5.9 to  $24 \times 10^9$  PFU/m<sup>2</sup>. As can be seen in Table 5, one adverse event (grade 4

Table 5. Dose-Limiting Toxicities

Dose Level	Regimen	Doses ( $\times 10^9$ PFU/m $^2$ )	Dose Being Escalated	No. of Patients Enrolled	No. of Patients With DLT	Type of DLT
1	Single	5.9	First dose	6	1	1 pt with diarrhea (gr 4)
2	Single	12	First dose	6	0	None
3	Single	24	First dose	5	1*	1 pt with dyspnea (gr 3) and hypoglycemia (gr 3)
4	Repeat	5.9 $\times$ 3	N/A†	6	1	1 pt with dyspnea‡ (gr 4)
5	Repeat	12 $\times$ 3	N/A†	7	0	None
6	Desensitizing	12, 24 $\times$ 2	Second dose	4	0	None
7	Desensitizing	12, 48 $\times$ 2	Second dose	3	0	None
8	Desensitizing	12, 72 $\times$ 2	Second dose	5	0	None
9	Desensitizing	12, 96 $\times$ 2	Second dose	12	1	1 pt with acute dosing reaction   (gr 3) * back pain
10	Desensitizing	12, 144 $\times$ 2	Second dose	13	3¶	1 pt with tremors (gr 3) and dehydration (gr 3); 1 pt with dehydration (gr 3); 1 pt with hypoxia (gr 3) which occurred during rigors
11	Two-week	12, 96 $\times$ 5	N/A†	7	0	None
12	Two-week	12, 120 $\times$ 5	N/A†	5	0	None#

Abbreviations: DLT, dose-limiting toxicity; pt, patient; gr, grade; N/A, not applicable.

\*Grade 2 hypotension was also observed at this dose level (in three of five patients) and was the only dose-dependent toxicity in the single-dose regimen. Dose escalation was stopped to allow an outpatient dosing regimen. The dose of  $12 \times 10^9$  PFU/m $^2$  was therefore established as the outpatient MTD for the first dose with grade 2 hypotension as dose limiting.

†This patient with baseline compromised lung function had worsening of underlying pulmonary infiltrate after PV701 dosing. See the Results, which describes an association of lung/pleural tumor involvement and respiratory adverse events.

‡Tolerance of repeat dosing tested rather than dose escalation.

§This patient with baseline extensive lung metastases and bilateral pleural effusions experienced grade 4 dyspnea after the first dose of  $5.9 \times 10^9$  PFU/m $^2$  and did not experience any recurrence with doses 2 and 3 or during a second course.

||One patient of the first seven of this cohort had an acute dosing reaction (grade 3 back pain) due to the  $96 \times 10^9$  PFU/m $^2$  dose. The infusion rate was slowed and five more patients enrolled onto this dose level and only one mild dosing reaction occurred (grade 1 abdominal discomfort).

¶Dose escalation of the second dose was stopped at  $144 \times 10^9$  PFU/m $^2$  due to the occurrence of three dose-limiting toxicities in this cohort.

#One patient with preexisting compromised lung function died of respiratory failure after receiving only the desensitizing dose of  $12 \times 10^9$  PFU/m $^2$ . There were no dose-limiting toxicities seen with the dose of  $120 \times 10^9$  PFU/m $^2$ .

diarrhea) that met the definition of DLT was seen in the first cohort ( $5.9 \times 10^9$  PFU/m $^2$ ) of six patients. Severe diarrhea was not seen on subsequent higher dose levels when loperamide was given prophylactically at the first sign of gastrointestinal side effects. No DLTs were seen in six patients in the  $12 \times 10^9$  PFU/m $^2$  cohort. At the  $24 \times 10^9$  PFU/m $^2$  dose level, a DLT (grade 3 dyspnea) occurred in a patient with a lung tumor mass and baseline signs of pulmonary infiltrate. This patient also experienced grade 3 hypoglycemia. Dyspnea and hypoglycemia were not considered dose dependent in this trial because severe dyspnea was associated with patients having lung/pleural tumor masses and hypoglycemia only occurred in patients with diabetes (discussed in Hypoglycemia in Patients on Oral Hypoglycemic Agents or Insulin).

In the single-dose regimen, the only dose-dependent toxicity was grade 2 hypotension, which occurred in three of five patients in the  $24 \times 10^9$  PFU/m $^2$  cohort. Because the intention was to establish an outpatient dosing regimen, dose 1 was not escalated further. The dose of  $12 \times 10^9$

PFU/m $^2$  was therefore established as the outpatient MTD for the first dose with grade 2 hypotension as dose limiting.

The repeat-dose regimen tested for the presence of any cumulative toxicity at two dose levels ( $5.9/5.9/5.9$  and  $12/12/12 \times 10^9$  PFU/m $^2$ ) in a total of 13 patients. As indicated in Table 5, only a single DLT was observed (grade 3 dyspnea), which occurred in a breast cancer patient with baseline bilateral pleural effusions dosed at  $5.9/5.9/5.9 \times 10^9$  PFU/m $^2$ , the lower of the two dose levels. No cumulative toxicity was seen. A dose of  $12 \times 10^9$  PFU/m $^2$  was therefore chosen as a first dose (or "desensitizing dose") for escalation of the second and subsequent doses in the desensitizing regimen.

In the desensitizing regimen, one DLT was observed in the first four cohorts with a total of 24 patients (Table 5). This acute dosing reaction (grade 3 back pain) at  $12/96/96$  was attributed to the infusion rate (see Acute Dosing Reactions above), which was slowed for subsequent patients. In the  $12/144/144 \times 10^9$  PFU/m $^2$  cohort of 13 patients, three DLTs were observed and dose escalation was

stopped. These events were seen after the  $144 \times 10^9$  PFU/m<sup>2</sup> dose: grade 3 tremors and dehydration in an 81-year-old woman, grade 3 dehydration in a 75-year-old man, and grade 3 hypoxia associated with 30 minutes of rigors in a man with lung cancer.

For patients in the 2-week regimen, repeat doses lower than  $144 \times 10^9$  PFU/m<sup>2</sup> were therefore tested. There was no significant difference in adverse event profile or laboratory values for repeat doses of 96 or  $120 \times 10^9$  PFU/m<sup>2</sup> given five times over 2 weeks, no cumulative toxicity was seen, and patients tolerated equally well either of these doses. Therefore, the dose of  $120 \times 10^9$  PFU/m<sup>2</sup> was determined to be the second dose MTD.

#### *Serious Adverse Events and Deaths*

Seven cases of dehydration requiring intravenous fluids and/or hospitalization were noted. Most of these cases were associated with significant nausea/vomiting and/or diarrhea. These events were reversible and did not result in lasting effects. As discussed above, patients over age 70 were at increased risk for flu-like grade 3 adverse events.

Three patients with baseline bacterial infections were administered PV701 and had episodes of sepsis after PV701 therapy. Two patients had a baseline urinary tract infection. The other patient had baseline fever in the week before beginning PV701 treatment and had baseline bacteremia immediately before his first dose of PV701.

There were five patient deaths, four of which were clearly attributed to progressive disease occurring during the 4-week reporting period. The remaining death occurred in a 55-year-old man with renal carcinoma metastatic to the lungs. At baseline, he had compromised pulmonary function as a result of previous lobectomies, lobar atelectasis, and an 8-cm metastasis in one of the two remaining lobes. In addition, he was status postradical nephrectomy with a 4-cm tumor metastasis in his remaining adrenal gland. This patient was enrolled in the  $12/120 \times 5$  doses  $\times 10^9$  PFU/m<sup>2</sup> dose level. After an initial (and only) PV701 dose of  $12 \times 10^9$  PFU/m<sup>2</sup>, he experienced grade 3 hypotension that required intravenous hydration and 48 hours of hospitalization. Three days later, he was admitted to a local community hospital with complaints of fatigue, lethargy, and severe respiratory distress. Mechanical ventilation was advised but was declined. The patient died as a result of respiratory failure approximately 12 hours later. At autopsy, an enlarged subcarinal lymph node ( $5 \times 4 \times 3$  cm) filled with partially hemorrhagic and necrotic tumor tissue was reported as well as a metastatic tumor that measured  $8 \times 7 \times 6$  cm just below the inferior pleural surface of the left upper pulmonary lobe. Histologic sections of the left lung were reported as showing the presence of localized thrombi only



in the tumor vessels with tumor necrosis and severe edema/inflammation only in the tumor-bearing lung and mild to absent in the non-tumor-bearing lung. Inflammation was not reported in any other organ.

#### *Response Assessment*

Seventeen patients were not eligible for response assessment. Twelve patients were removed from the study before a radiographic response assessment because of toxicity or worsening baseline symptoms. Three patients were taken off the study for progressive disease. One patient was removed as a result of noncompliance, and one was removed to receive radiation therapy.

Of the 62 patients who were eligible for response assessment, 14 had freedom from tumor progression for 4 to 30+ months and two had radiographic evidence of major responses. A complete response was documented in a 51-year-old man with tonsillar (squamous cell) carcinoma. At the time of enrollment, this patient had disease progression during cisplatin and radiation therapy (with the most recent treatment given in September 1998) as noted by a radiographic increase during the preceding 3 months. After a baseline MRI scan in January 1999 (Fig 1A) demonstrating a 1.5-cm tumor in the pharynx, he received PV701 at the  $12/96/96 \times 10^9$  PFU/m<sup>2</sup> dose level. After one cycle, he achieved a radiographic complete response as evidenced by resolution of the tumor on MRI. Follow-up scans after months 2, 3, and 5 of therapy confirmed the radiographic complete response (Fig 1B). The patient was noncompliant and discontinued therapy between months 5 and 7. An MRI scan at month 7 indicated disease progression elsewhere in the pharynx (lateral oropharyngeal wall).


A partial response was documented in a 79-year-old man who had colon carcinoma and had failed capecitabine, 5-FU, and irinotecan. He had not received any chemotherapy in the 2 months before his enrollment into the PV701 study at the  $12/72/72 \times 10^9$  PFU/m<sup>2</sup> dose level. At baseline, he had two liver metastases, the largest one well-circumscribed and measuring 10 cm in maximal dimension (Fig 2A). His CT scans at month 1 (Fig 2B) and month 2 after therapy showed overall tumor regression of greater than 70%. In addition, immediately after dosing there was a spike in carcinoembryonic antigen level (approximately 4.5-fold increase) followed by a drop to steady-state levels at 79% below baseline, shown elsewhere to be further indicative of a response.<sup>27</sup> Progression-free survival of 10 months was observed in this patient. Seven other patients with diverse malignancies (including mesothelioma, melanoma, colon carcinoma, breast carcinoma, pancreatic carcinoma, and carcinoid) had measurable tumor reduction, although less than 50% of the total tumor burden.



**Fig 1.** Complete response in a man with tonsillar carcinoma. (A) Baseline MRI image showing a 1.5-cm tumor at the junction of the right tongue base and tonsillar pillar. (B) MRI image at month 3 showing complete resolution of tumor.

#### *Replacement of Tumor by Inflammatory Cells on Histologic Examination*

During the course of PV701 therapy, one patient had tumor tissue removed for electron microscopic examination and other tissue analysis. This 46-year-old man, who had bulky peritoneal mesothelioma that had progressed after debulking surgery and intraperitoneal doxorubicin/cisplatin and IFN- $\gamma$ , was enrolled at the 12/48/48  $\times 10^9$  PFU/m<sup>2</sup> dose level in January 1999. During 30 monthly courses of PV701, he has remained free from progression, has no disease-related symptoms, experienced an improvement in performance status (to Eastern Cooperative Oncology Group 0), gained muscle mass, and retained a high level of physical activity. CT scans performed on a monthly basis



**Fig 2.** Partial response in a man with colon carcinoma. (A) Baseline CT scan demonstrating 10-cm liver metastasis. (B) CT scan at month 1 demonstrating the response.

have shown up to a 35% reduction in bidimensional measurable disease ( $270 \text{ cm}^2$  at study entry). Elective surgery to debulk disease 2 weeks after his last dose of the eighth course (in the eleventh month of PV701 administration) was unsuccessful. However, histologic examination showed a significant fraction of the tumor mass replaced by an active inflammatory process with edema in all sections of tumor (Fig 3A and 3B). This process consisted predominantly of plasma cells. Lymphoid follicles with germinal centers were also evident in the tumor, indicating an active immune reaction (Fig 3C). Electron microscopy revealed PV701 particles at tumor cell membranes (Fig 3D). The plasma cell infiltrate and secondary lymphoid follicles were not present in previous sections of tumor parenchyma taken before enrollment. A normal skin sample removed at the time of the patient's tumor excision did not show any




Fig 3. Microscopic tumor sections after 8 PV701 courses. Tumor parenchyma (H&E histologic stain) showing (A) inflammation/edema, (B) plasma cell infiltrate, and (C) lymphoid follicle/aggregate. (D) Electron micrograph shows particles consistent with PV701 budding from the tumor cell membrane.

evidence of inflammation. His serum neutralizing antibody titer had reached a plateau level of 1:2,560 at the time of the tissue examination.

In another case, a different pattern of tumor inflammation was seen. Autopsy sections from a patient who had advanced pleural mesothelioma and died of progressive disease (tumor obstruction of the inferior vena cava) were reviewed. Lung metastases displayed a mononuclear inflammatory infiltrate mainly at the periphery of the larger metastases and throughout the smaller tumor masses (Fig 4A and 4B). Also observed in the lung metastases were signs of tumor necrosis, including multifocal areas at the tumor periphery (Fig 4A). The portion of lung without tumor was free of any signs of inflammation (Fig 4C). A similar pattern was seen in his liver metastasis (Fig 4D), which showed mononuclear inflammatory cells infiltrating

the tumor but not uninvolved liver distal from the tumor (Fig 4E). A diffuse mononuclear inflammatory infiltrate was also seen in a mesenteric metastasis (Fig 4F) but not in the adjacent normal tissue. No such inflammatory process was present in the original biopsy of the primary tumor preceding PV701 treatment. Unlike the previous case of the patient with peritoneal mesothelioma, there was no sign of tumor regression in this particular patient and no samples of tumor tissue were obtained for viral analysis.

#### DISCUSSION

Among the various clinical tests of replication-competent viruses<sup>22-25,28,29</sup> (Stojdl et al, manuscript submitted for publication), the phase I dose escalation study reported here is the first study in humans to determine an MTD for systemic (intravenous) administration. PV701, an oncolytic




Fig 4. Histologic (H&E) tissue sections from a patient with pleural mesothelioma. (A, B) Lung metastasis showing inflammation and multifocal necrosis. (C) Lung uninvolved by tumor. (D) Liver metastasis showing inflammation. (E) Liver uninvolved by tumor. (F) Mesenteric metastasis showing inflammation.

strain of Newcastle disease virus was studied because it demonstrated preclinical activity against a wide range of human tumors *in vitro* and *in vivo* and is active by the intravenous route. Importantly, Newcastle disease virus has previously been shown to lack pathogenicity in humans after low-dose administration<sup>3,8,20,21,30</sup> mainly as a component of oncolysate tumor vaccines.<sup>8,20,21</sup> This phase I study characterized the toxicity profile for intravenous PV701 dosing and demonstrated the feasibility and potential benefit of systemic (intravenous) oncolytic virus administration.

As expected from previously published reports on Newcastle disease virus serologic surveys,<sup>31,32</sup> only one of the 32 patients tested was found to have neutralizing antibody before administration of the virus. After dosing with PV701, the majority (27 of 29) of patients tested developed varying levels of neutralizing antibody. Neutralizing antibody titers, even with multiple courses, reached a moderate plateau level of ~1:2,560, including a patient who received repeated cycles of PV701 for more than 18 months. Of potential clinical significance, signs of efficacy (eg, tumor regressions) were observed in patients after formation of these antibody titers.

Low levels of viral shedding were observed and found generally to be transient. Recovery of virus from sputum was rare, was of low level, occurred only after the first cycle of virus administration, and always cleared within a maximum of 14 days. Recovery of virus from urine after the first cycle of PV701 was more common but again did not persist, being cleared within 3 weeks. Transient viruria was observed less frequently after subsequent cycles but did occur despite the presence of neutralizing antibodies. Ultimately, the incidence of transient viruria diminished to zero among patients who received PV701 for seven or more cycles. Relative to the environmental impact of shedding on the most susceptible host species (chickens), the observed levels of PV701 shedding are orders of magnitude below the standard avian vaccine dose required for an antibody response.<sup>33,34</sup>

The low and transient viral shedding seen in this study may be part of the explanation for the lack of any observed human-to-human transmission seen with PV701. This finding is in agreement with data from other clinical trials using Newcastle disease virus<sup>3</sup> and with other human experience with the virus.<sup>3,6</sup>

The acute toxicity of PV701 principally consisted of flu-like symptoms (fever, chills, fatigue, headache, nausea, vomiting, and diarrhea) and dose-dependent hypotension that occurred 4 to 24 hours after PV701 dosing. Older patients ( $\geq 70$  years) and those with anemia (hemoglobin < 11 g/dL) were found to be more likely to experience flu-like symptoms of greater severity. Acute toxic effects have been

shown in animal models to be a result of Newcastle disease virus-induced release of proinflammatory cytokines, including type I IFNs and TNF- $\alpha$ .<sup>35-39</sup> Levels of type I IFN, IFN- $\gamma$ , TNF- $\alpha$ , and IL-6 were elevated in patients in this study after the first dose of PV701, with levels first detected by 6 hours and peaking at hour 20. This pattern paralleled the time course of the flu-like symptoms (eg, fever was consistently noted between hours 4 and 20). Antipyretics and antidiarrheal agents reduced the incidence and severity of these toxicities.

Just as tachyphylaxis develops in mammals, including humans, with repeat IFN and TNF dosing,<sup>40-42</sup> a striking reduction in the incidence and severity of PV701-mediated acute toxicity on repeat dosing was observed (Table 4). This phenomenon, termed "desensitization," was first observed with PV701 in the rodent models and applies to effects on toxicity but not efficacy. In preclinical testing using human tumor xenografts in athymic mice, efficacy increased with repeat dosing and toxicity was markedly reduced. After intravenous administration of  $3 \times 10^8$  PFU, mice tolerated subsequent intravenous doses of  $1 \times 10^{10}$  PFU, indicating at least a 10-fold increase in the MTD.<sup>2</sup> As fully predicted by these preclinical studies, this desensitization phenomenon allowed a 10-fold increase in the MTD observed in this trial with a first dose MTD of  $12 \times 10^9$  PFU/m<sup>2</sup> and a second dose MTD of  $120 \times 10^9$  PFU/m<sup>2</sup>. The reduction in adverse event profile seen with the second PV701 dose compared with the first dose paralleled the reduction in serum cytokine levels seen after second PV701 dose, suggesting a causative role of proinflammatory cytokines in the clinical toxicity of PV701. As seen preclinically in both immunodeficient and immunocompetent mice, this desensitization phenomenon in patients does not depend on the development of antibodies to PV701 because it is seen as early as 2 days after the first PV701 dose (when antibodies are not detectable).

Desensitization also occurred with respect to transient drops in platelet and WBC counts. IFN and TNF- $\alpha$  are known to cause transient changes in blood cell counts as a result of margination.<sup>40,43-47</sup> A previous study by Merrigan et al,<sup>30</sup> using single doses (from  $10^6$  to  $10^8$  PFU/patient) of Newcastle disease virus, orders of magnitude below the doses tested in this trial, verified a dose-dependent induction of IFN in the serum of 17 patients along with fever and a transient leukopenia. In the present study, these transient hematologic changes were induced by the first dose of PV701. Leukocyte and platelet levels recovered during the first course of repeat dosing, even when doses were 10-fold higher than the first dose. Importantly, the leukopenias and thrombocytopenias were not correlated with signs of infection or bleeding, and the degree and rate of recovery did not

require therapeutic intervention. The lack of cumulative effects seems to be consistent with margination of leukocytes and platelets rather than a consumptive process.

There was no observed cumulative toxicity associated with prolonged repeated PV701 dosing including a total of 116 repeat courses given to a total of 39 patients. One patient has had more than 30 courses of PV701 with no evidence of an adverse effect on any organ system. Because of desensitization and the lack of cumulative toxicity, an overall dose intensification of more than 100-fold was achieved in this trial (Table 1).

Tumor site-specific inflammatory reactions were also seen. In this study, two patients with palpable tumors (colon cancer with a scalp metastasis and tongue cancer) developed inflammation and edema localized to the tumor sites. Histologic confirmation of tumor site-specific inflammation was obtained from representative patients. In one patient with metastatic pleural mesothelioma, tumor necrosis and a mononuclear cell inflammatory infiltrate were observed only at tumor sites without any involvement of normal tissue, including tissue adjacent to disease sites (Fig 4). Evidence of such tumor inflammation as seen in this trial raises a question about the determination of responses by traditional imaging criteria, especially in future phase II trials.

Tumor site-specific effects were also observed in patients with tumor involvement of the lung and liver. Oxygen desaturation, for example, was observed only in patients with pulmonary/pleural-based tumors (13 of 55 with involvement v zero of 24 without;  $P < .01$ ). Significant elevation in liver enzymes was also limited, occurring only in patients with liver metastases (18 of 38 v zero of 41;  $P < .01$ ). In addition, there was no evidence of generalized hepatocyte toxicity because total serum protein and clotting times remained comparable to baseline. Furthermore, the typical pattern of liver enzymes (elevated gamma glutamyltransferase and alkaline phosphatase disproportionate to transaminases; and  $AST > ALT$ ) was indicative of pressure on the canalicular and cholangioles from a space-occupying effect rather than hepatocellular damage from hepatitis.<sup>48,49</sup> Of cautionary note for future trials, patients with malignancy extensively replacing normal lung tissue, particularly if baseline pulmonary dysfunction exists, seem to be at risk for severe pulmonary toxicity. One such patient with pre-existing compromised lung function died of respiratory failure. Severe edema and inflammation was found local-

ized to the tumor-bearing lung along with thrombosis confined to the tumor vessels.

Response assessment was not the focus of this phase I study, especially because, in this dose escalation study, most patients received low, potentially suboptimal dose intensities (Table 1). However, 62 patients were assessable. Evidence of efficacy included progression-free survival from 4 to more than 30 months in 14 patients who had clear evidence of disease progression before initiation of PV701. Furthermore, two radiographic objective responses (complete response and partial response) were documented and seven other patients had measurable tumor reductions, although not to the degree of a partial response. A 46-year-old man with advanced peritoneal mesothelioma unresponsive to intraperitoneal chemotherapy, with bulky disease (four 8- to 10-cm masses with total bidimensional measurable disease of 270 cm<sup>2</sup>) at baseline, has received more than 30 courses of PV701, has maintained an improved performance status (Eastern Cooperative Oncology Group 0), has had a radiographic minor response (of 35% tumor regression), and has experienced no cumulative toxicity. Evidence of a direct oncolytic effect of PV701 in this patient was found on biopsy after 11 months of PV701 administration. PV701 particles were observed budding from tumor cell membranes, and the tumor mass was extensively filled with mononuclear inflammatory cells (especially plasma cells) replacing tumor, indicating that PV701 had gained access to the tumor and was replicating there despite the presence of serum neutralizing antibody. In comparison to this patient with one of the largest tumor burdens enrolled onto the study, the patient with the smallest tumor burden (1.5 cm, tonsillar cancer) experienced a complete radiographic response after three doses of PV701.

Collectively, these observations support the concept that systemic therapy with the replication-competent virus PV701 can provide a novel and potentially important therapy for patients with solid tumors, including those unresponsive to standard therapy. Moreover, long-term intravenous virus therapy seems to be feasible in humans and may play an important role in the treatment of solid tumors. Additional clinical studies of PV701 have begun.

#### ACKNOWLEDGMENT

We thank the dedicated nurses for patient care and study coordination. Phoebe L. Stewart, PhD, UCLA School of Medicine, is gratefully acknowledged for independent review of the electron micrographs. We thank John Bell, PhD, for permission to cite his unpublished review article on oncolytic viruses.

## REFERENCES

1. Roberts S, Buasen PT, Incao BA, et al: PV701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts. *Proc Am Assoc Cancer Res* 42:454, 2001 (abstr 2441)
2. Lorence RM, Roberts S, Groene WS, et al: Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. *Proc Am Assoc Cancer Res* 42:454, 2001 (abstr 2442)
3. Lorence RM, Roberts MS, Groene WS, et al: Replication-competent, oncolytic Newcastle disease virus for cancer therapy, in Hernalz Driever P, Rabkin SD (eds): *Replication-Competent Viruses for Cancer Therapy*, Monographs in Virology (vol. 22). Basel, Switzerland, Karger, 2001, pp 160-182
4. Nelson NJ: Scientific interest in Newcastle disease virus is reviving. *J Natl Cancer Inst* 91:1708-1710, 1999
5. Kleiman MB: Newcastle disease virus, in Lennette EH (ed): *Laboratory Diagnosis of Viral Infections*. New York, NY, Marcel Dekker, 1992, pp 567-571
6. Alexander DJ: Newcastle disease and other avian paramyxoviruses. *Rev Sci Tech* 9:443-462, 2000
7. Reichard KW, Lorence RM, Cascino CJ, et al: Newcastle disease virus selectively kills human cancer cells. *J Surg Res* 52:448-453, 1992
8. Schirrmacher V, Ahlert T, Probstle T, et al: Immunization with virus-modified tumor cells. *Semin Oncol* 25:677-696, 1998
9. Termeer CC, Schirrmacher V, Brocher EB, et al: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. *Cancer Gene Ther* 7:316-323, 2000
10. Schirrmacher V, Bai L, Umansky V, et al: Newcastle disease virus activates macrophages for anti-tumor activity. *Int J Oncol* 16:363-373, 2000
11. Reichard KW, Lorence RM, Cascino CJ, et al: Selective replication of Newcastle disease virus in cancer cells is associated with virus-induced cell fusion. *Proc Am Assoc Cancer Res* 33:521, 1992 (abstr)
12. Roberts MS, Lorence RM, Groene WS, et al: Treatment of neoplasms with viruses. International Patent Publication No. WO 99/18799, 1999
13. Stojdl DF, Lichty B, Knowles S, et al: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. *Nat Med* 6:821-825, 2000
14. Jaramillo ML, Abraham N, Bell JC: The interferon system: A review with emphasis on the role of PKR in growth control. *Cancer Invest* 13:327-338, 1995
15. Stark GR, Kerr IM, Williams BR, et al: How cells respond to interferons. *Ann Rev Biochem* 67:227-264, 1998
16. Gil J, Esteban M: Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): Mechanism of action. *Apoptosis* 5:107-114, 2000
17. Lorence RM, Reichard KW, Katubig BB, et al: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. *J Natl Cancer Inst* 86:1228-1233, 1994
18. Lorence RM, Katubig BB, Reichard KW, et al: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. *Cancer Res* 54:6017-6021, 1994
19. Cassel WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. *Cancer* 18:863-868, 1965
20. Cassel WA, Murray DR: Treatment of stage II malignant melanoma patients with Newcastle disease virus oncolysate. *Nat Immun Cell Growth Regul* 7:351-352, 1988
21. Batliwalla FM, Bateman BA, Serrano D, et al: A 15-year follow up of AJCC stage III malignant melanoma patients treated post-surgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. *Mol Med* 4:783-794, 1998
22. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 6:879-885, 2000
23. Markert JM, Medlock MD, Rabkin SD, et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. *Gene Ther* 7:867-874, 2000
24. Ganly I, Kirn D, Eckhardt SG, et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. *Clin Cancer Res* 6:798-806, 2000
25. Nemunaitis J, Cunningham C, Buchanan A, et al: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. *Gene Ther* 8:746-759, 2001
26. Hao D, Rowinsky EK, Smetzer LA, et al: A phase I and pharmacokinetic study of intravenous (IV) p53 gene therapy with RPR/INGN-201 in patients (pts) with advanced cancer. *Proc Am Soc Clin Oncol* 20:262a, 2001 (abstr 1045)
27. Quayle JB: Tumour lysis as a factor affecting blood levels of CEA. *Br J Cancer* 46:213-219, 1982
28. Kirn D: Systemic administration of replication-selective adenoviruses. *Eur J Cancer* 37:S65, 2001 (suppl 3, abstr 105)
29. Cattaneo R (ed): *Replicating vectors for gene therapy*. *Gene Ther* 8:S1-S13, 2001 (suppl 1)
30. Merigan TC, DeClercq E, Finkelstein MS, et al: Clinical studies employing interferon inducers in man and animals. *Ann N Y Acad Sci* 173:746-759, 1970
31. Miller LT, Yates VJ: Reactions of human sera to avian adenoviruses and Newcastle disease virus. *Avian Dis* 15:781-788, 1971
32. Charan S, Mahajan VM, Agarwal LP: Newcastle disease virus antibodies in human sera. *Indian J Med Res* 73:303-307, 1981
33. Newcastle disease vaccine. United States Code of Federal Regulations. Title 9, Part 113, Section 329, 1999
34. Thorton DH: Quality control of vaccines, in Alexander DJ (ed): *Newcastle Disease*. Boston, MA, Kluwer Academic Publishers, 1988, pp 347-365
35. Raj NB, Cheung SC, Rosztoczy I, et al: Mouse genotype affects inducible expression of cytokine genes. *J Immunol* 148:1934-1940, 1992
36. Baron S, Buckler CE: Circulating interferon in mice after intravenous injection of virus. *Science* 141:1061-1063, 1963
37. Brehm G, Kirchner H: Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid. *J Interferon Res* 6:21-28, 1986
38. Busam KJ, Bauer TM, Bauer J, et al: Interleukin-6 release by rat liver macrophages. *J Hepatol* 11:367-373, 1990
39. Lorence RM, Rood PA, Kelley KW: Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor- $\alpha$  and augmentation of its cytotoxicity. *J Natl Cancer Inst* 80:1305-1312, 1988

40. Savage PD, Muss HB: Renal cell cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): *Biologic Therapy of Cancer* (ed 2). Philadelphia, PA, JB Lippincott, 1995, pp 373-387
41. Fraker DL, Stovroff MC, Merino MJ, et al: Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. *J Exp Med* 168:95-105, 1988
42. Fraker DL, Pass HI, Alexander HR, et al: Biologic therapy with TNF: Systemic administration and isolation-perfusion, in DeVita VT, Hellman S, Rosenberg SA (eds): *Biologic Therapy of Cancer* (ed 2). Philadelphia, PA, JB Lippincott, 1995, pp 329-345
43. Chapman PB, Lester TJ, Casper ES, et al: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. *J Clin Oncol* 5:1942-1951, 1987
44. Creagan ET, Ahmann DL, Green SJ, et al: Phase II study of recombinant leukocyte A interferon (rIFN- $\alpha$ A) in disseminated malignant melanoma. *Cancer* 54:2844-2849, 1984
45. Creaven PJ, Brenner DE, Cowens JW, et al: A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. *Cancer Chemother Pharmacol* 23:186-191, 1989
46. Feldman ER, Creagan ET, Schaid DJ, et al: Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. *Am J Clin Oncol* 15:256-259, 1992
47. Quesada JR, Talpaz M, Rios A, et al: Clinical toxicity of interferons in cancer patients: A review. *J Clin Oncol* 4:234-243, 1986
48. Pincus MR, Schaffner JA: Assessment of liver function, in Henry JB (ed): *Clinical Diagnosis and Management by Laboratory Methods* (ed 19). Philadelphia, PA, WB Saunders, 1996, pp 253-267
49. Pincus MR, Zimmerman HJ, Henry JB: Clinical enzymology, in Henry JB (ed): *Clinical Diagnosis and Management by Laboratory Methods* (ed 19). Philadelphia, PA, WB Saunders, 1996, pp 268-295

The ideas and opinions expressed in this publication do not necessarily reflect those of the American Society of Clinical Oncology or the Publisher. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. Neither the American Society of Clinical Oncology nor the Publisher assumes any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this publication. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

# Antitumor effects of Newcastle Disease Virus *in vivo*: Local versus systemic effects

V. SCHIRRMACHER<sup>1</sup>, A. GRIESBACH<sup>1</sup> and T. AHLERT<sup>2</sup>

<sup>1</sup>Division of Cellular Immunology, Tumorimmunology Program, German Cancer Research Center Heidelberg;

<sup>2</sup>Biotechnologisches Praxislabor, Technologiepark, Heidelberg, Germany

Received January 24, 2001; Accepted February 20, 2001

**Abstract.** Newcastle Disease Virus (NDV) has interesting anti-neoplastic and pleiotropic immune stimulatory properties. The virus preferentially replicates in and kills tumor cells and appears to be safe and to varying degrees effective in phase II-clinical studies in the US and in Europe. Here we have compared various lytic and non-lytic strains of NDV with regard to their antitumor effects after local or systemic application. As tumor models we used human metastatic melanoma xenotransplants in nude mice and murine metastatic colon carcinoma (CT26), renal carcinoma (RENCA) and lymphoma (ESb) cell lines. Intra or peri-tumoral application of NDV or NDV infected tumor cells showed more pronounced antitumor activity than systemic application even when in the latter case much higher dose ranges were used. In the CT26 colon carcinoma model the non-lytic strain Ulster showed stronger antitumor activity than the lytic strain 73T. In the human MeWo melanoma xentransplant model strong anti-tumor bystander effects were observed by 20% admixture of melanoma cells pre-infected *in vitro* with NDV (either strain Ulster or Italien). Virus therapy of pre-established human melanomas by intra-tumoral injection of NDV was effective with the lytic strain Italien but not with the non-lytic strain Ulster. Systemic anti-metastatic effects were never observed with NDV alone in contrast to previous results obtained with NDV modified tumor vaccines.

## Introduction

Interest in the exploitation of the anti-neoplastic properties of viruses (1) and, in particular, of the avian paramyxovirus NDV (2) has steadily increased in recent years, as exemplified and reviewed by two recent editorials (3,4). Decades of NDV

treatment of cancer patients (4) have resulted in various modes of application e.g. i) use of oncolytic virus strains such as NDV 73T for production of oncolysates as tumor vaccines (5), ii) use of non-lytic virus strains such as NDV Ulster for production of live virus-modified tumor cell vaccines (6-11) and iii) use of veterinary vaccine strains such as MTH-68 as inhalation vaccine for systemic treatment and non-specific immune stimulation (12).

No comparative studies have hitherto been performed to evaluate the relative effectiveness of different NDV strains in different tumor systems and different modes of application. Here we report on experiments performed over many years with metastasizing human and animal tumors in mice in which we tested various NDV applications, either locally at the tumor site or systemically. We demonstrate antitumor activity of various NDV strains when applied locally but not after systemic (i.v. or i.p.) application.

## Materials and methods

**Virus source and propagation.** NDV 73T (5) was obtained in 1990 from W.A. Cassel (Atlanta, GA, USA). NDV Italien was obtained in 1986 from H.D. Klenk (University Giessen, Germany). NDV Ulster 2 C (13) was obtained in 1984 from P.H. Russel (University London, England). All virus batches were propagated in embryonated chicken eggs, purified by ultracentrifugation and quantified by hemagglutination as described previously (8). Viral replication tests *in vitro* in various tumor lines revealed monocyclic replication for NDV Ulster and multicyclic replication for NDV Italien (14). For NDV 73T multicyclic replication and tumor selectivity have been described (15,16).

**Tumor lines and cell culture.** MeWo-Met is a metastatic subline of the human melanoma line MeWo. It was obtained by us as follows: MeWo tumors were first established in nude mice by s.c. transfer of newborn mouse brain aggregates (17) which had been invaded *in vitro* for 48 h with MeWo tumor cells. Eventually occurring lung metastases in mice were re-isolated and cultured. The *in vivo* selected variant line MeWo-Met was shown to be more metastatic than the parental line MeWo. ESb-LCI represents a metastasizing murine lymphoma, genetically marked with the bacterial lacZ-gene. This allowed visualization at the single cell level of scattered metastatic spread in the liver (18). The murine BALB/c derived renal cell

**Correspondence to:** Professor V. Schirrmacher, German Cancer Research Center, Division of Cellular Immunology, Tumorimmunology Program, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany  
E-mail: v.schirrmacher@dkfz-heidelberg.de

**Key words:** Newcastle Disease Virus, metastatic melanoma, xenotransplant, colon carcinoma, renal carcinoma, lymphoma

carcinoma line RENCA (19) and the BALB/c derived chemically-induced colon carcinoma line CT26 (20) were obtained from I.J. Fiddler (MD Anderson Cancer Center, Houston, TX, USA). All tumor lines were cultured in RPMI-1640 medium as described (21).

**Virus infection of tumor cells *in vitro* and functional testing for T cell stimulatory capacity.** The various tumor cell lines were infected with NDV according to our standard protocol (6,8). It was shown that virus infection of tumor cells introduced adhesive and costimulatory immune functions in the tumor cells (21,22). Furthermore, modification of tumor cells by a low dose of NDV (standard protocol) caused augmentation of tumor specific T-cell responses in the absence of an antiviral response (23). This augmented response was a result of CD4 and CD8 immune T cell cooperation (24) and involved the induction of interferon- $\alpha$ ,  $\beta$  (25). To stimulate a secondary tumor specific cytotoxic T cell (CTL) response *in vitro*, tumor cell membrane integrity and viability was found to be very important (26). Tumor cell lysates were ineffective (26,27). Virus potentiation of tumor vaccine T cell stimulatory capacity required cell surface binding but not infection (28). The viral hemagglutinin-neuraminidase molecule (HN) was shown upon transfection to augment peptide specific CTL responses (29).

**Tumor transplantation and treatment.** For tumor transplantation, the indicated numbers of cells from the cultured tumor lines were suspended in 100  $\mu$ l PBS and injected at the sites indicated. Local intra- or peri-tumoral NDV treatment was performed with a syringe with the indicated amounts of virus suspended in 100  $\mu$ l PBS and distributed as well as possible. Systemic treatment was performed by tail vein or intraperitoneal injection of the indicated amount of virus in 100  $\mu$ l PBS.

**Evaluation of tumor growth and host survival.** Local tumor growth was determined at regular intervals by calculating either the tumor area or the tumor diameter from two rectangular determinations [(a+b)/2].

**Biostatistics.** The log-rank test was applied to evaluate whether the survival curves of experimental groups differed significantly. Exact tests were performed by means of the software package Stat Xact (Cytel, San Diego, CA, USA).

## Results

**Local antitumor effects of NDV.** We first tested local anti-tumor effects of NDV on human tumor cells xenotransplanted into nude (*nu/nu*) mice. As model system we used a selected invasive and metastatic subline of the melanoma line MeWo (MeWo-Met). Four weeks after s.c. transplantation of  $5 \times 10^6$  cells large tumors developed (Fig. 1A). When mice were injected instead with the same amount of tumor cells infected before with NDV Ulster according to an established protocol (6,8) no tumor growth in nude mice could be detected (data not shown). In order to test for a possible bystander effect of virus-infected tumor cells on non-infected tumor cells we





Figure 1. Effects of admixture of virus infected human melanoma (MeWo-Met) cells on the growth of non-infected human melanoma cells in nude mice. A, shows photographs of tumor-bearing control mice one month after s.c. inoculation of  $5 \times 10^6$  non-infected MeWo-Met cells. B, shows almost complete absence of tumors in the experimental group in which  $1 \times 10^6$  NDV Ulster infected MeWo-Met cells were admixed to the  $5 \times 10^6$  uninfected tumor cells.

admixed  $1 \times 10^6$  NDV-infected MeWo-Met cells. As can be seen from the photographs of Fig. 1B, taken four weeks later, a dramatic tumor growth inhibitory effect was seen with addition of only 20% of virus infected cells. Only just visible tumors had developed up to this time point with NDV Ulster, a result the more remarkable because NDV Ulster was shown to have only a monocyclic replication cycle in tumor cells. The effect cannot be explained by virus spreading because the tumor cell produced virions are non-infectious (8,28).

Fig. 2A shows the whole kinetics of tumor growth in the two groups of Fig. 1 as well as from a third group. In the third group,  $5 \times 10^6$  melanoma cells were admixed with  $1 \times 10^6$  NDV Italien infected melanoma cells. The virulent strain Italien in contrast to the avirulent strain Ulster can spread *in vivo* and infect neighbouring tumor cells. It can be seen that over a time course of two months there was a complete suppressive effect on tumor growth when using NDV Italian and a strong but not complete suppressive effect with the non-virulent strain NDV Ulster.

Fig. 2B shows the direct therapeutic effects of virus treatment of established human melanoma cells growing in nude mice. After xenotransplantation of the metastatic MeWo subline MeWo-Met, local tumors were first allowed to establish for about four weeks. Treatment then started by intra-tumoral injection of either virus free allantoic fluid in the control group or of allantoic fluid containing NDV Italian. This treatment



**Figure 2.** Antitumor effects of NDV in a human melanoma (MeWo-Met) xenotransplant model. **A**, antitumor effects of human melanoma cells infected *in vitro* with either non-lytic NDV Ulster or lytic NDV Italian upon admixture to an excess of uninfected MeWo-Met human melanoma cells upon xenotransplantation into BALB/c (nu/nu) mice. Note the complete tumor-suppressive effect of NDV Italian infected cells which could be explained by virus spreading and oncolysis of the non-infected cells. The tumor suppressive effects of NDV Ulster infected cells, the results of which are also shown in Fig. 1, cannot be explained by virus spreading because the tumor cell produced virions of this NDV strain are non-infectious (21). **B**, virus therapy of established human MeWo-Met melanoma xenotransplanted in nude mice. After four weeks when the tumor had established, the virus therapy was started by direct inoculation of the oncolytic strain NDV Italian using 25-250 hemagglutinating units per treatment. The time points of treatment are indicated by arrows. Mice of the control group were injected in parallel with virus-free allantoic fluid. The virus or the control fluid was inoculated directly into the tumor by means of multiple inoculations. Tumor growth was followed regularly over a period of about 3 months. Note that in the control groups there was a continuous and steady tumor growth while under virus therapy the growth of this highly malignant human melanoma line was stopped.

or the control fluid was inoculated directly into the tumor by means of multiple inoculations and the tumor growth in the treated and control groups was followed regularly over a period of about three months. It can be seen that further growth of this highly malignant human melanoma line was completely prevented in the group treated with the NDV Italian. In contrast, in the control group there was a continuous and steady tumor growth.

At the end of the experiment the animals were sacrificed and investigated histologically. While the virus treatment had profoundly affected the local tumor growth it had not significantly affected metastasis formation by this tumor. Similar numbers of metastases were seen in lungs and livers of control and virus treated animals. Nine from 21 organs (lung, liver, spleen) were metastasized in the control as well as in the virus treated group (Table I).

Nevertheless, the local therapy effects on established human tumors were highly significant. Such effects could only be obtained with virulent NDV strains with multicyclic replication patterns and ability to spread within the neighbouring tumor tissue. Only marginal antitumor effects were obtained in this test system with less aggressive NDV strains including Ulster with monocyclic replication patterns and no ability of virus spread to neighbouring tumor tissue (data not shown).

Three syngeneic aggressive metastasizing animal tumor models which are frequently in use for evaluating therapy effects, were used to further investigate possible effects of tumor cell infection by NDV on tumor growth and host survival. Fig. 3 shows survival curves of either BALB/c mice injected with syngeneic CT26 colon carcinoma cells (A) or of DBA/2 mice injected with syngeneic ESb-LCI lymphoma cells (B). While mice of the control groups were injected s.c. with non-infected tumor cells from established cell lines, mice of the experimental groups were injected with the same number of cells pre-infected *in vitro* with the non-virulent strain NDV Ulster at a dose of 30 hemagglutinating units (HU) per 10<sup>7</sup> cells. As can be seen, mice injected with the virus modified tumor cells survived significantly longer than the controls.


We also tested for virus therapy of established CT26 colon carcinomas. CT26 tumors growing intradermally in BALB/c mice were treated at a size of 6-8 mm diameter with either NDV Ulster or NDV 73T. As can be seen from Fig. 4, the intra- and peri-tumoral application of 1,000 HU of NDV Ulster

**Table I.** Absence of anti-metastatic activity of systemic NDV in a human melanoma xenotransplant model.

	Tumor transplantation <sup>a</sup> day 0	NDV treatment <sup>b</sup> days 42, 54, 76	No. of animals with metastases <sup>c</sup>			Animals without metastasis
			in lung	liver	spleen	
I	MeWo-Met. s.c.	-	5	4	0	0
II	MeWo Met. s.c.	+	3	5	1	1

<sup>a</sup>MeWo-Met cells (a metastatic subline of MeWo-Met) were co-cultured for 5 days with embryonic mouse tissue aggregates to select for invasive cells. Five hundred tumor cells containing tissue aggregates were then transplanted s.c. in the neck region of nu/nu mice. Seven mice per group. <sup>b</sup>Treatment was started when primary tumors had reached a size of at least 0.5 cm diameter. The control group (I) received 200 µl virus-free allantois fluid i.v. and the experimental group (II) 200 µl NDV Italian allantois fluid i.v. The virus dose was 2,000 HU.


<sup>c</sup>Presence or absence of organ metastases was verified by standard histopathology.




**Figure 3.** Antitumor effects of tumor cell infection by non-lytic NDV Ulster on their growth in syngeneic mice. Cells from the BALB/c derived colon carcinoma line CT26 (A) or from the DBA/2 derived aggressive lymphoma line ESB-LCI were *in vitro* infected with NDV Ulster (30 HU per  $10^7$  cells) and then transplanted in parallel with untransfected cells. CT26 cells were used at a dose of  $10^6$  cells s.c. (A) and ESB-LCI cells at a dose of  $10^4$  cells intradermally (B). Note that there was a significant prolongation of host survival in experimental vs control groups.

at days 8, 11, 13 and 15 after tumor inoculation led to complete tumor remission by day 40. In contrast, a similar treatment with NDV 73T had no antitumor effect in this colon carcinoma.

Having tested xenogeneic and syngeneic tumor-host combinations we next investigated possible antitumor effects of NDV in allogeneic tumor-host combinations. When CT26 colon carcinoma cells with or without virus infection were transplanted into allogeneic but major histocompatibility complex (MHC) identical DBA/2 mice (10 mice per group) there was a 100% tumor take with non-infected CT26 and with NDV 73T infected CT26 cells while with NDV-Ulster infected CT26 cells there was only a 30% tumor take (Fig. 5A). The survival curves (Fig. 5B) of mice injected with CT26 or NDV 73T infected CT26 cells were similar and showed 30% survival after 2 months. In contrast, the survival curves of the mice injected with NDV Ulster infected CT26 cells were significantly different resulting in 70% long-term survivors. Thus, in the allogeneic strain DBA/2 in which CT26 tumor growth was less aggressive, the antitumor effect of NDV Ulster was stronger than in the syngeneic situation (compare Fig. 5B with Fig. 3A). Surprisingly, the oncolytic strain NDV 73T showed no antitumor activity in the CT26 tumor model.



**Figure 4.** Virus therapy of established CT26 murine colon carcinomas in syngeneic mice.  $10^6$  CT26 cells were injected i.d. into BALB/c mice (10 mice per group) and allowed to grow for 8 days to a size of 6-8 mm diameter. While the control group I was left untreated, group II was treated with NDV Ulster and group III with NDV 73T. Treatment consisted of intra- and peritumoral injection of 1,000 HU NDV at days 8, 11, 13 and 15 (see arrows). Note that in group II there was complete tumor remission although with large individual variations, while in group III there was progressive tumor growth similar to the control.



**Figure 5.** Effects of NDV infection on murine CT26 colon carcinoma cell growth in allogeneic MHC identical but minor histocompatibility antigen different DBA/2 mice. BALB/c derived CT26 colon carcinoma cells were infected *in vitro* with either non-lytic NDV Ulster or with lytic NDV-73T (30 HU/ $10^7$  cells).  $10^6$  non-infected or NDV infected cells were inoculated into three groups of mice (10 animals per group). A, shows the maximal tumor take rate and B, shows their long-term survival. Note that the virus strain NDV Ulster conferred in this model a significant antitumor effect although it is much less virulent than the lytic strain 73T which showed no significant effect.




Figure 6. Effects of NDV infection on murine RENCA renal carcinoma cell growth in allogeneic DBA/2 mice. Cells of the BALB/c derived renal carcinoma cell line RENCA were *in vitro* infected with either NDV Ulster or NDV 73T as in Fig. 5 using 100 HU/10<sup>6</sup> cells. 10<sup>6</sup> of such virus infected or non-infected cells were then transplanted s.c. into allogeneic but MHC identical DBA/2 mice and tumor take (A), growth and host survival (B) was followed over a period of two months. Note that in this tumor model there were significant antitumor effects upon infection with both types of NDV.

neither in syngeneic BALB/c (Fig. 4) nor in allogeneic DBA/2 mice (Fig. 5B).

The results of a similar experiment performed with RENCA renal carcinoma cells which are also derived from BALB/c mice are illustrated in Fig. 6. While RENCA tumor take in DBA/2 mice with uninfected cells was 70%, with NDV Ulster infected cells it was only 30% and with NDV 73T infected cells 40%. From Fig. 6B it can be seen that long-term survival corresponded to these tumor take rates. Thus, both NDV Ulster and NDV 73T showed in this allogeneic renal carcinoma model similar trends of antitumor activity, both with respect to local tumor growth (Fig. 6A) and host survival (Fig. 6B). No antitumor activity was seen, however, with RENCA tumor cells modified by NDV Ulster or NDV 73T in syngeneic BALB/c mice (data not shown).

**Systemic effects of NDV on metastatic tumor cells.** In order to evaluate possible systemic effects of intravenously inoculated NDV on tumor micrometastases and host survival we first inoculated metastatic murine tumor cells intra-venously and then treated them with either NDV Ulster or NDV 73T. Fig. 7 illustrates results obtained in the ESb lymphoma model of DBA/2 mice. In the experiments reported in Fig. 7A we first




Figure 7. Absence of systemic antitumor effects of intravenous NDV treatment on disseminated ESb lymphoma cells. A, groups of DBA/2 mice (8 per group) were injected i.v. with decreasing numbers of syngeneic ESb-LCI cells to establish a tumor dose-survival response relationship. B, groups of DBA/2 mice (8 per group) were injected at day 0 i.v. with 10<sup>4</sup> ESb-LCI cells and then treated i.v. at days 1, 4 and 8 with the indicated amounts of NDV Ulster or NDV 73T. Note that in comparison to the untreated group (V) there was no shift of the survival curves to the right upon treatment.

titrated the tumor cells i.v. and tested for host survival. When using 10<sup>4</sup> or 10<sup>3</sup> tumor cells i.v., all the mice died within 2-3 weeks while with 10<sup>2</sup> and 10<sup>1</sup> tumor cells only about 50% of the mice died within 2 months. We then performed the NDV treatment experiment with 10<sup>4</sup> ESb tumor cells. It can be seen that no survival benefit could be obtained by any of the NDV treatments applied. This was true in spite of the fact that we used rather high virus doses, repeated injections and different strains of NDV. A similar experiment, in which NDV was applied i.p. instead of i.v. (Fig. 8) also showed no improvement in survival. Instead there was a significant ( $p=0.0003$ ) detrimental effect of systemic high-dose ( $>10,000$  HU) NDV treatment on host survival. A survival benefit should have been seen if the tumor dose had been reduced by 1 or 2 log 10 units (see A). The results, however, do not exclude small antitumor effects (<90% reduction in cell number; e.g. from 10<sup>4</sup> to 10<sup>3</sup>).

We also tried to affect intravenously injected CT26 carcinoma cells (10<sup>6</sup> cells in DBA/2 mice) by treating them 1, 4 and 7 days later with different doses of either NDV Ulster or NDV 73T. Both viruses were applied at rather high doses of




Figure 8. Absence of systemic antitumor effects of intraperitoneal NDV treatment on disseminated ESb lymphoma cells. The experimental protocol was similar to that of Fig. 7. Note that in comparison to the untreated group (IV) there was a shift of the survival curves to the left (shorter survival) rather than to the right upon treatment.




Figure 9. Absence of systemic antitumor effects of intravenous NDV treatment on disseminated murine CT26 colon carcinoma cells in allogeneic DBA/2 mice. Groups of DBA/2 mice (8 per group) were injected at day 0 i.v. with  $10^6$  CD26 cells and then treated i.v. at days 1, 4 and 7 with the indicated amounts of NDV Ulster or NDV 73T. Note that in comparison to the untreated group (I) there was no shift of the survival curves to the right upon treatment.

either 5,000 or 1,000 HU. As can be seen from the survival curves of Fig. 9 in none of the treated groups a survival benefit was seen. There was a significant detrimental effect on host survival when using 5,000 HU NDV 73T.

## Discussion

We previously reported on the usefulness of NDV for introducing into autologous live cell tumor vaccines pleiotropic immune stimulatory properties (8,21,30,31). Recently we showed that NDV infection of human melanoma cells induces a B7.1/B7.2 independent T cell costimulatory activity (32). In these studies we used the non-lytic, non-virulent lentogenic NDV strain Ulster in order to maintain tumor cell viability and immunogenicity (26,27). Cassel *et al.* introduced

the oncolytic strain NDV 73T which they used to produce viral oncolysates as vaccines for post-operative treatment of stage II malignant melanoma (5). Csاتary *et al.* applied the veterinary vaccine strain MTH-68 directly as an inhalation vaccine to late stage cancer patients (12). With all these different concepts and modes of application clinical benefits have been reported (5,9-12,30). Nevertheless, it remains unclear under which circumstances each virus strain might give optimal therapeutic effects.

In this study we compared three NDV strains, two of which (73T and Italien) are lytic and one (Ulster) non-lytic. All three strains share the property of replication competence in tumor cells. NDV Ulster has an abortive and monocyclic replication mode in tumor cells and cannot spread in tumor tissue because the tumor produced virus progeny is non-infectious (8,21). In contrast, NDV 73T and Italien show lytic and multicyclic replication cycles in tumor cells and can spread in tumor tissue (14-16). Lytic in contrast to non-lytic strains can be quantified by their cytopathic plaque-forming activity. For the purpose of this study, the amounts of virus of the different strains applied was based on hemagglutinating activity, a property shared by all NDV strains.

Before discussing the results obtained in detail, some additional information should be given. i) Infection of tumor cells by non-lytic NDV Ulster ( $30 \text{ HU}/10^7 \text{ cells}$ ) eventually leads to tumor cell death. The time period required for this depends on the tumor line tested and varies between 1-3 days (31; unpublished data). This period is sufficient for elicitation of a delayed-type hypersensitivity (DTH) skin response which peaks 24-48 h after vaccination. ii) NDV Ulster and NDV 73T were shown to replicate selectively in tumor cells (8,15,16). No viral replication has been reported in normal cells except for embryonic chicken chorioallantoic membrane epithelial cells (8). iii) Due to this tumor selectivity of virus replication, negative side effects of NDV in cancer patients have hardly ever been reported (4). iv) In spite of tumor selectivity of NDV replication, the virus also binds to normal cells which express sialic acid containing gangliosides as ubiquitous virus receptors. Systemically applied NDV is therefore likely absorbed by normal cells thereby preventing its targeting to remote tumor tissue. To overcome possible absorption by normal cells we used in this study for systemic application much higher virus doses than for local application.

Antitumor effects of NDV were much stronger when applied locally than systemically. This can be best exemplified with the aggressive ESb-LCI mouse lymphoma tumor model. Fig. 3 illustrates highly significant local antitumor effects which were observed when  $10^4$  tumor cells that were transplanted i.d. had been infected before with 0.03 HU NDV Ulster ( $30 \text{ HU}/10^7 \text{ cells}$ ). The same number of tumor cells, injected i.v., could not be successfully treated systemically by NDV being applied either i.v. (Fig. 7) or i.p. (Fig. 8). The virus doses were applied even three times and ranged from 1,000 and 5,000 HU (Fig. 7) to 10,000 and 50,000 HU (Fig. 8). They were thus  $10^3$ - $10^6$  times higher than in Fig. 3. Neither strain Ulster nor strain 73T were capable, upon systemic delivery, to transfer any tumor protective activity which should have translated into improved survival, as in Fig. 3. The difference between local effectiveness and systemic ineffectiveness of NDV in this test system is most likely due to

ineffective tumor targeting of NDV upon systemic application. The virus doses used in Fig. 8 were close to maximal tolerated doses (MTD) and caused already detrimental effects on overall survival.

NDV Ulster and 73T were equally capable of conferring local antitumor activity in the murine renal carcinoma model RENCA. When virus-infected and non-infected tumor cells were transplanted into DBA/2 mice, there was a reduction in % tumor take (Fig. 6A) and an improvement in % survival (Fig. 6B) in case of virus-infected cells. Since in syngeneic BALB/c mice no such differences were observed between virus-infected and non-infected RENCA tumor cells, the virus-mediated effects seen in Fig. 6 are likely due to helper effects in immune responses of DBA/2 mice against BALB/c RENCA tumor associated minor histocompatibility antigens.

In the BALB/c derived murine CT26 colon carcinoma tumor model NDV 73T was totally ineffective. Neither local (Fig. 4) nor systemic (Fig. 9) antitumor effects could be observed. Even in allogeneic DBA/2 mice no local antitumor effects could be seen with NDV 73T (Fig. 5). In contrast, NDV Ulster was locally effective in this tumor, both in syngeneic (Fig. 4) and allogeneic (Fig. 5) mice. Even when CT26 tumors were first allowed to establish in syngeneic mice to a size of 6-8 mm diameter, subsequent intra- and peri-tumoral treatment with strain Ulster caused complete tumor remissions (Fig. 4) while treatment with strain 73T was ineffective. Infection with NDV Ulster was also effective in human MeWo-Met melanoma cells to suppress tumor growth in nude mice upon subsequent transplantation. Even admixture of only  $1 \times 10^6$  NDV infected to  $5 \times 10^6$  uninfected melanoma cells before transplantation caused a long-lasting tumor suppressive effect (Fig. 1). Since this virus has no cytopathic plaque-forming activity and cannot spread to neighbouring uninfected tumor cells, the observed tumor suppressive effect is most likely due to a local NDV mediated bystander effect. We recently reported on the capacity of NDV strain Ulster and La Sota to activate murine macrophages towards antitumor cytotoxicity (33). This might explain the observed bystander effect.

When human MeWo-Met cells were first allowed to establish for four weeks in nude mice to form large primary tumors (see Fig. 1A) and then treated by intra-tumoral injection of either non-lytic NDV Ulster or lytic NDV Italien, only the latter treatment which allows for intra-tumoral virus spread and cytopathic plaque formation was effective (Fig. 2B). In this experimental situation the above discussed macrophage-mediated local bystander effect was either not in function or insufficient to prevent further tumor growth.

In conclusion, the major message of this study is that antitumor activity of NDV is stronger when applied locally, in close proximity to the tumor, than when applied systemically. The local antitumor effects are likely to involve various mechanisms such as direct viral oncolysis (with lytic strains), tumor cell apoptosis (with lytic and non-lytic strains) and host bystander effects mediated for example via activated macrophages (33-35), and activated T cells (21,23-28,31,32). Since direct targeting of tumor metastases by systemic NDV application appears to be difficult, targeting of metastases via activated antitumor immune T cells remains another option. Activation of such antitumor immune T cells can be tried either by active immunization with tumor vaccines as we do

(6,7,9-11,30) or by *ex vivo* stimulation in which case immunotherapy would be tried by adoptive transfer of such activated immune T cells.

### Acknowledgements

We thank the following people for providing us with NDV virus batches: P.H. Russel (London, England), W.A. Cassel (Atlanta, USA) and H.D. Klenk (Giessen, Germany). We furthermore thank I.J. Fidler (Houston, USA) for the cell lines RENCA and CT26. We also acknowledge the help of A. Benner (DKFZ, Heidelberg) with biostatistics.

### References

- Sinkovics J and Horvath J: New development in the virus therapy of cancer: a historical review. *Intervirology* 36: 193-214, 1993.
- Cassel WA and Garret RE: Newcastle disease virus as an anti-neoplastic agent. *Cancer* 7: 863-868, 1965.
- Kenney S and Pagano JS: Viruses as oncolytic agents: a new age for 'therapeutic' viruses? *J Natl Cancer Inst* 86: 1185-1186, 1994.
- Nelson NJ: News: scientific interest in Newcastle Disease Virus is reviving. *J Natl Cancer Inst* 91: 1708-1710, 1999.
- Cassel WA, Murray DR and Phillips HS: A phase 2 study on the postsurgical management of stage 2 malignant melanoma with a Newcastle disease virus oncolysate. *Cancer* 52: 856-860, 1983.
- Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T and Appelhans B: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. *Int J Cancer* 37: 569-577, 1986.
- Schirrmacher V and Heicappell R: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. *Clin Exp Metastasis* 5: 147-156, 1987.
- Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. *Gene Ther* 6: 63-73, 1999.
- Pomer S, Schirrmacher V, Thiele R, Lohrke H and Staehler G: Tumor response and 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN- $\alpha$  2b. *Int J Oncol* 6: 947-954, 1995.
- Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagemüller E, Nagel M and Saeger H-D: Newcastle Disease Virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. *Clin Cancer Res* 2: 21-28, 1996.
- Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Häcker B, Schumacher M and Schirrmacher V: Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. *J Clin Oncol* 15: 1354-1366, 1997.
- Csatary LK, Eckhardt S, Lukacs I, et al: Attenuated veterinary virus vaccine for the treatment of cancer. *Cancer Detect Prev* 17: 619-627, 1993.
- McFerran JB and Nelson R: Some properties of an avirulent Newcastle Disease Virus. *Arch Virol* 34: 64-74, 1971.
- Ahlert T and Schirrmacher V: Isolation of a human melanoma adapted Newcastle Disease Virus mutant with highly selective replication patterns. *Cancer Res* 50: 5962-5968, 1990.
- Reichard KW, Lorence RM, Cascino CJ, et al: Newcastle Disease Virus selectively kills human tumor cells. *J Surg Res* 52: 448-453, 1992.
- Lorence RM, Reichard KW, Katubig BB, et al: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle Disease Virus therapy. *J Natl Cancer Inst* 86: 1228-1233, 1994.
- Waller CA, Braun M and Schirrmacher V: Quantitative analysis of cancer invasion *in vitro*: comparison of two new assays and of tumor sublines with different metastatic capacity. *Clin Exp Metastasis* 4: 73-89, 1986.
- Krüger A, Schirrmacher V and von Hoegen P: Scattered micrometastasis visualized at the single cell level: detection and re-isolation of lacZ labeled metastasized lymphoma cells. *Int J Cancer* 58: 275-284, 1994.

19. Murphy GP and Hrushesky WJ: A murine renal cell carcinoma. *J Natl Cancer Inst* 50: 1013-1025, 1973.
20. Corbett TH, Griswold DP, Roberts BJ, Peckham JC and Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. *Cancer Res* 35: 2423-2439, 1975.
21. Jurianz K, Haas C, Hubbe M, Ertel C, Brunner G, Altevogt P, Schirrmacher V and von Hoegen P: Adhesive function of Newcastle Disease Virus hemagglutinin in tumor-host interaction. *Int J Oncol* 7: 539-545, 1995.
22. Haas C, Ertel C, Gerhards R and Schirrmacher V: Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. *Int J Oncol* 13: 1105-1115, 1998.
23. Von Hoegen P, Weber E and Schirrmacher V: Modification of tumor cells by a low dose of Newcastle Disease Virus: augmentation of the tumor-specific T cell response in the absence of an anti-viral response. *Eur J Immunol* 18: 1159-1166, 1988.
24. Schild H-J, von Hoegen P and Schirrmacher V: Modification of tumor cells by a low dose of Newcastle Disease Virus: II. Augmented tumor specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. *Cancer Immunol Immunother* 28: 22-28, 1988.
25. Von Hoegen P, Zawatzky R and Schirrmacher V: Modification of tumor cells by a low dose of Newcastle Disease Virus: III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon, alfa, beta. *Cell Immunol* 126: 80-90, 1990.
26. Schirrmacher V and von Hoegen P: Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. *Vaccine Res* 2: 183-196, 1993.
27. Schirrmacher V, Griesbach A and Zangemeister U:  $\gamma$ -Irradiated viable tumor cells as whole cell vaccines can stimulate *in situ* syngeneic anti-tumor CTL and DTH reactivity while tumor cell lysates elicit only DTH reactivity. *Vaccine Res* 3: 31-48, 1994.
28. Schirrmacher V, Haas C, Bonifer R and Ertel C: Virus potentiation of tumor vaccine T cell stimulatory capacity requires cell surface binding but not infection. *Clin Cancer Res* 3: 1135-1145, 1997.
29. Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. *Eur J Immunol* 23: 2592-2596, 1993.
30. Schirrmacher V, Ahlert T, Pröbstle T, Steiner HH, Herold-Mende C, Gerhards R and Hagemüller E: Immunization with virus modified tumor cells. *Semin Oncol* 25: 677-696, 1998.
31. Schirrmacher V, Jurianz K, Roth CH, Griesbach A, Bonifer R and Zawatzky R: Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanisms in MLTC-CML cultures. *Int J Oncol* 14: 205-215, 1999.
32. Termeer CC, Schirrmacher V, Bröcker EB and Becker JC: Newcastle-Disease-Virus infection induces a B7-1/B7-2 independent T-cell-costimulatory activity in human melanoma cells. *Cancer Gene Ther* 7: 316-323, 2000.
33. Schirrmacher V, Bai L, Appelhans B, Umansky V, Yu L, Xing Y and Qian Z: Newcastle Disease Virus activates macrophages for antitumor activity. *Int J Oncol* 16: 363-373, 2000.
34. Umansky V, Shatrov VA, Lehmann V and Schirrmacher V: Induction of nitric oxide synthesis in macrophages by Newcastle Disease Virus is associated with activation of nuclear factor- $\kappa$ B. *Int Immunol* 8: 491-498, 1996.
35. Zorn U, Dallmann I, Große J, *et al.*: Induction of cytokines and cytotoxicity against tumor cells by Newcastle Disease Virus. *Cancer Biother* 9: 225-234, 1994.